Movatterモバイル変換


[0]ホーム

URL:


US20030114647A1 - Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules - Google Patents

Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules
Download PDF

Info

Publication number
US20030114647A1
US20030114647A1US10/119,546US11954602AUS2003114647A1US 20030114647 A1US20030114647 A1US 20030114647A1US 11954602 AUS11954602 AUS 11954602AUS 2003114647 A1US2003114647 A1US 2003114647A1
Authority
US
United States
Prior art keywords
poly
moiety
active
group
mpeg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/119,546
Inventor
J. Harris
Francesco Veronese
Paolo Caliceti
Oddone Schiavon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Shearwater Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shearwater CorpfiledCriticalShearwater Corp
Priority to US10/119,546priorityCriticalpatent/US20030114647A1/en
Assigned to NEKTAR THERAPEUTICS AL, CORPORATIONreassignmentNEKTAR THERAPEUTICS AL, CORPORATIONCHANGE OF NAME (SEE DOCUMENT FOR DETAILS).Assignors: SHEARWATER CORPORATION
Publication of US20030114647A1publicationCriticalpatent/US20030114647A1/en
Priority to US10/634,970prioritypatent/US7419600B2/en
Priority to US12/284,357prioritypatent/US7786221B2/en
Assigned to NEKTAR THERAPEUTICSreassignmentNEKTAR THERAPEUTICSMERGER (SEE DOCUMENT FOR DETAILS).Assignors: NEKTAR THERAPEUTICS AL, CORPORATION
Priority to US12/849,683prioritypatent/US8354477B2/en
Priority to US13/714,917prioritypatent/US8546493B2/en
Abandonedlegal-statusCriticalCurrent

Links

Images

Classifications

Definitions

Landscapes

Abstract

Multi-armed, monofunctional, and hydrolytically stable polymers are described having the structure
Figure US20030114647A1-20030619-C00001
wherein Z is a moiety that can be activated for attachment to biologically active molecules such as proteins and wherein P and Q represent linkage fragments that join polymer arms polyaand polyb, respectively, to central carbon atom, C, by hydrolytically stable linkages in the absence of aromatic rings in the linkage fragments. R typically is hydrogen or methyl, but can be a linkage fragment that includes another polymer arm. A specific example is an mPEG disubstituted lysine having the structure
Figure US20030114647A1-20030619-C00002
where mPEGaand mPEGbhave the structure CH3O—(CH2CH2O)nCH2CH2— wherein n may be the same or different for polya- and polyb- and can be from 1 to about 1,150 to provide molecular weights of from about 100 to 100,000.

Description

Claims (67)

What is claimed is:
1. A polymeric derivative represented by the structure
Figure US20030114647A1-20030619-C00038
wherein polyaand polybare nonpeptidic and substantially nonreactive water soluble polymeric arms that may be the same or different, wherein C is carbon, wherein P and Q comprise linkage fragments that may be the same or different and join polymeric arms polyaand polyb, respectively, to C by hydrolytically stable linkages in the absence of aromatic rings in said linkage fragments, wherein R is a moiety selected from the group consisting of H, substantially nonreactive moieties, and linkage fragments having attached thereto by a hydrolytically stable linkage in the absence of aromatic rings one or more nonpeptidic and substantially nonreactive water soluble polymeric arms, and wherein Z comprises a moiety selected from the group consisting of moieties having a single site reactive toward nucleophilic moieties, sites that can be converted to sites reactive toward nucleophilic moieties, and the reaction product of a nucleophilic moiety and moieties having a single site reactive toward nucleophilic moieties.
Figure US20030114647A1-20030619-C00039
wherein polyaand polybmay be the same or different and are selected from the group consisting of linear poly(ethylene glycol), poly(vinyl alcohol), poly(propylene glycol), poly(oxyethylated glycerol), poly(oxyethylated sorbitol), poly(oxyethylated glucose), poly(oxazoline), poly(acryloylmorpholine), and poly(vinylpyrrolidone); wherein C is carbon; wherein P and Q comprise linkage fragments that may be the same or different and join polymeric arms polyaand polyb, respectively, to C by hydrolytically stable linkages selected from the group consisting of amide, amine, ether, carbamate, thiourea, urea, thiocarbamate, thiocarbonate, thioether, thioester, and dithiocarbamate linkages; wherein R is a moiety selected from the group consisting of H, substantially nonreactive moieties, and linkage fragments having attached thereto by a hydrolytically stable linkage in the absence of aromatic rings one or more nonpeptidic and substantially nonreactive water soluble polymeric arms; and wherein Z comprises a moiety selected from the group consisting of carboxyl, hydroxyl, trifluoroethylsulfonate, isocyanate, isothiocyanate, N-hydroxylsuccinimidyl ester, N-hydroxylsuccinimidyl carbonate, p-nitrophenylcarbonate, trichlorophenylcarbonate, aldehyde, vinylsulfone, maleimide, iodoacetamide, and iminoesters.
Figure US20030114647A1-20030619-C00042
comprising the steps of:
a) reacting nonpeptidic, water soluble, monofunctional polymers of the structure polya-W and polyb-W with a linker moiety having at least two active sites for which W is selective, a reactive site Z for which W is not selective, and a moiety R which is substantially nonreactive, wherein W is an active electrophilic moiety selected from the group consisting of trifluoroethylsulfonate, isocyanate, isothiocyanate, active esters, active carbonates, aldehyde, vinylsulfone, maleimide, iodoacetamide, and iminoesters, and may be the same or different on polyaand polyb, wherein polyaand polybare polymer moieties selected from the group consisting of poly(ethylene glycol), poly(vinyl alcohol), poly(propylene glycol), poly(oxyethylated glycerol), poly(oxyethylated sorbitol), poly(oxyethylated glucose), poly(oxazoline), poly(acryloylmorpholine), and poly(vinylpyrrolidone) and may be the same or different, and wherein the active sites of the linker moiety are nucleophilic sites selected from the group consisting of amino, thiol, and hydroxyl; and
b) forming hydrolytically stable linkages P and Q, which may be the same or different, in the absence of aromatic rings between the polymer and the linker moiety that are selected from the group consisting of amide, amine, ether, carbamate, thiourea, urea, thiocarbamate, thiocarbonate, thioether, thioester, and dithiocarbamate linkages.
US10/119,5461995-01-102002-04-10Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and moleculesAbandonedUS20030114647A1 (en)

Priority Applications (5)

Application NumberPriority DateFiling DateTitle
US10/119,546US20030114647A1 (en)1995-01-102002-04-10Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules
US10/634,970US7419600B2 (en)1995-01-102003-08-05Method for purifying a branched water-soluble polymer
US12/284,357US7786221B2 (en)1995-01-102008-09-20Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules
US12/849,683US8354477B2 (en)1995-01-102010-08-03Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US13/714,917US8546493B2 (en)1995-01-102012-12-14Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules

Applications Claiming Priority (5)

Application NumberPriority DateFiling DateTitle
US37106595A1995-01-101995-01-10
US08/443,383US5932462A (en)1995-01-101995-05-17Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US09/140,907US20010007765A1 (en)1995-01-101998-08-27Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules
US93986701A2001-08-272001-08-27
US10/119,546US20030114647A1 (en)1995-01-102002-04-10Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
US93986701AContinuation1995-01-102001-08-27

Related Child Applications (2)

Application NumberTitlePriority DateFiling Date
US10/634,970ContinuationUS7419600B2 (en)1995-01-102003-08-05Method for purifying a branched water-soluble polymer
US12/284,357ContinuationUS7786221B2 (en)1995-01-102008-09-20Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules

Publications (1)

Publication NumberPublication Date
US20030114647A1true US20030114647A1 (en)2003-06-19

Family

ID=27005224

Family Applications (7)

Application NumberTitlePriority DateFiling Date
US08/443,383Expired - LifetimeUS5932462A (en)1995-01-101995-05-17Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US09/140,907AbandonedUS20010007765A1 (en)1995-01-101998-08-27Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules
US10/119,546AbandonedUS20030114647A1 (en)1995-01-102002-04-10Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules
US10/634,970Expired - Fee RelatedUS7419600B2 (en)1995-01-102003-08-05Method for purifying a branched water-soluble polymer
US12/284,357Expired - Fee RelatedUS7786221B2 (en)1995-01-102008-09-20Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules
US12/849,683Expired - Fee RelatedUS8354477B2 (en)1995-01-102010-08-03Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US13/714,917Expired - Fee RelatedUS8546493B2 (en)1995-01-102012-12-14Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules

Family Applications Before (2)

Application NumberTitlePriority DateFiling Date
US08/443,383Expired - LifetimeUS5932462A (en)1995-01-101995-05-17Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US09/140,907AbandonedUS20010007765A1 (en)1995-01-101998-08-27Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules

Family Applications After (4)

Application NumberTitlePriority DateFiling Date
US10/634,970Expired - Fee RelatedUS7419600B2 (en)1995-01-102003-08-05Method for purifying a branched water-soluble polymer
US12/284,357Expired - Fee RelatedUS7786221B2 (en)1995-01-102008-09-20Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules
US12/849,683Expired - Fee RelatedUS8354477B2 (en)1995-01-102010-08-03Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US13/714,917Expired - Fee RelatedUS8546493B2 (en)1995-01-102012-12-14Multi-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules

Country Status (3)

CountryLink
US (7)US5932462A (en)
AU (1)AU4755596A (en)
WO (1)WO1996021469A1 (en)

Cited By (74)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20040268425A1 (en)*2003-03-052004-12-30Deliatroph Pharmaceuticals, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20050009988A1 (en)*2003-05-232005-01-13Harris J. MiltonPolymer derivatives having particular atom arrangements
US20050090650A1 (en)*1995-01-102005-04-28Harris J. M.Purified polymers for modification of surfaces and molecules
US20050170404A1 (en)*2004-02-022005-08-04Ambrx, Inc.Modified human growth hormone polypeptides and their uses
US20050260186A1 (en)*2003-03-052005-11-24Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060019347A1 (en)*2004-07-212006-01-26Ambrx, Inc.Biosynthetic polypeptides utilizing non-naturally encoded amino acids
WO2006009901A2 (en)2004-06-182006-01-26Ambrx, Inc.Novel antigen-binding polypeptides and their uses
US20060104968A1 (en)*2003-03-052006-05-18Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20060135427A1 (en)*2004-12-222006-06-22Ambrx, Inc.Formulations of human growth hormone comprising a non-naturally encoded amino acid
WO2006019950A3 (en)*2004-07-162006-08-03Nektar Therapeutics Al CorpConjugates of a gm-csf moiety and a polymer
US20060275252A1 (en)*2003-05-232006-12-07Harris J MConjugates formed from polymer derivatives having particular atom arrangements
WO2008030558A2 (en)2006-09-082008-03-13Ambrx, Inc.Modified human plasma polypeptide or fc scaffolds and their uses
US20080107680A1 (en)*2004-12-222008-05-08Ambrx, Inc.Modified Human Growth Hormone
US20080153745A1 (en)*2005-08-182008-06-26Ambrx, In.Compositions of tRNA and uses thereof
US20080199909A1 (en)*2004-12-222008-08-21Ambrx, Inc.Methods for Expression and Purification of Recombinant Human Growth Hormone
US20080317670A1 (en)*2005-12-142008-12-25Ambrx, Inc.Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
US20090123367A1 (en)*2003-03-052009-05-14DelfmemsSoluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
WO2009067636A2 (en)2007-11-202009-05-28Ambrx, Inc.Modified insulin polypeptides and their uses
WO2010011735A2 (en)2008-07-232010-01-28Ambrx, Inc.Modified bovine g-csf polypeptides and their uses
US7736872B2 (en)2004-12-222010-06-15Ambrx, Inc.Compositions of aminoacyl-TRNA synthetase and uses thereof
WO2010077297A1 (en)2008-12-092010-07-08Halozyme, Inc.Extended soluble ph20 polypeptides and uses thereof
WO2011003886A1 (en)2009-07-062011-01-13Alize Pharma IiPegylated l-asparaginase
WO2011034604A2 (en)2009-09-172011-03-24Baxter Healthcare, S.A.Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US8012931B2 (en)2007-03-302011-09-06Ambrx, Inc.Modified FGF-21 polypeptides and their uses
US8093356B2 (en)2005-06-032012-01-10Ambrx, Inc.Pegylated human interferon polypeptides
WO2012012300A2 (en)2010-07-202012-01-26Halozyme, Inc.Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
US8114630B2 (en)2007-05-022012-02-14Ambrx, Inc.Modified interferon beta polypeptides and their uses
WO2012024452A2 (en)2010-08-172012-02-23Ambrx, Inc.Modified relaxin polypeptides and their uses
WO2012109387A1 (en)2011-02-082012-08-16Halozyme, Inc.Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
US8278418B2 (en)2008-09-262012-10-02Ambrx, Inc.Modified animal erythropoietin polypeptides and their uses
US8318154B2 (en)2008-04-282012-11-27Halozyme, Inc.Super fast-acting insulin compositions
WO2012174480A2 (en)2011-06-172012-12-20Halozyme, Inc.Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
WO2013040501A1 (en)2011-09-162013-03-21Pharmathene, Inc.Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
US8420792B2 (en)2006-09-082013-04-16Ambrx, Inc.Suppressor tRNA transcription in vertebrate cells
WO2013063155A2 (en)2011-10-242013-05-02Halozyme, Inc.Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
WO2013151774A1 (en)2012-04-042013-10-10Halozyme, Inc.Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
EP2662090A1 (en)2008-04-142013-11-13Halozyme, Inc.Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
WO2013185115A1 (en)2012-06-082013-12-12Sutro Biopharma, Inc.Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2014036492A1 (en)2012-08-312014-03-06Sutro Biopharma, Inc.Modified amino acids comprising an azido group
WO2014062856A1 (en)2012-10-162014-04-24Halozyme, Inc.Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2805964A1 (en)2009-12-212014-11-26Ambrx, Inc.Modified bovine somatotropin polypeptides and their uses
EP2805965A1 (en)2009-12-212014-11-26Ambrx, Inc.Modified porcine somatotropin polypeptides and their uses
WO2015003167A1 (en)2013-07-032015-01-08Halozyme, Inc.Thermally stable ph20 hyaluronidase variants and uses thereof
WO2015006555A2 (en)2013-07-102015-01-15Sutro Biopharma, Inc.Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015054658A1 (en)2013-10-112015-04-16Sutro Biopharma, Inc.Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US9121025B2 (en)2008-09-262015-09-01Ambrx, Inc.Non-natural amino acid replication-dependent microorganisms and vaccines
US9133495B2 (en)2006-09-082015-09-15Ambrx, Inc.Hybrid suppressor tRNA for vertebrate cells
WO2016033555A1 (en)2014-08-282016-03-03Halozyme, Inc.Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
WO2016061286A2 (en)2014-10-142016-04-21Halozyme, Inc.Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US9434778B2 (en)2014-10-242016-09-06Bristol-Myers Squibb CompanyModified FGF-21 polypeptides comprising an internal deletion and uses thereof
US9447401B2 (en)2011-12-302016-09-20Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US9488660B2 (en)2005-11-162016-11-08Ambrx, Inc.Methods and compositions comprising non-natural amino acids
EP3103880A1 (en)2008-02-082016-12-14Ambrx, Inc.Modified leptin polypeptides and their uses
US9567386B2 (en)2010-08-172017-02-14Ambrx, Inc.Therapeutic uses of modified relaxin polypeptides
EP3135690A1 (en)2012-06-262017-03-01Sutro Biopharma, Inc.Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2017094897A1 (en)2015-12-042017-06-08全薬工業株式会社Anti-il-17 aptamer having improved retention in blood
US9775889B2 (en)2008-03-062017-10-03Halozyme, Inc.Methods of treatment of cellulite
WO2018085493A1 (en)2016-11-042018-05-11Georgia State University Research Foundation, Inc.Endotoxin free asparaginase
US9993529B2 (en)2011-06-172018-06-12Halozyme, Inc.Stable formulations of a hyaluronan-degrading enzyme
WO2018237201A1 (en)2017-06-222018-12-27Catalyst Biosciences, Inc. MODIFIED MEMBRANE-LIKE SERINE PROTEASE-1 POLYPEPTIDES (MTSP-1) AND METHODS OF USE
US10266578B2 (en)2017-02-082019-04-23Bristol-Myers Squibb CompanyModified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019222435A1 (en)2018-05-162019-11-21Halozyme, Inc.Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020056066A1 (en)2018-09-112020-03-19Ambrx, Inc.Interleukin-2 polypeptide conjugates and their uses
WO2020082057A1 (en)2018-10-192020-04-23Ambrx, Inc.Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020140101A1 (en)2018-12-282020-07-02Catalyst Biosciences, Inc.Modified urokinase-type plasminogen activator polypeptides and methods of use
WO2020168017A1 (en)2019-02-122020-08-20Ambrx, Inc.Compositions containing, methods and uses of antibody-tlr agonist conjugates
WO2021183832A1 (en)2020-03-112021-09-16Ambrx, Inc.Interleukin-2 polypeptide conjugates and methods of use thereof
WO2022040596A1 (en)2020-08-202022-02-24Ambrx, Inc.Antibody-tlr agonist conjugates, methods and uses thereof
US11273202B2 (en)2010-09-232022-03-15Elanco Us Inc.Formulations for bovine granulocyte colony stimulating factor and variants thereof
WO2022212571A1 (en)2021-03-302022-10-06Jazz Pharmaceuticals Ireland Ltd.Dosing and administration of recombinant l-asparaginase
WO2022212899A1 (en)2021-04-032022-10-06Ambrx, Inc.Anti-her2 antibody-drug conjugates and uses thereof
US11613744B2 (en)2018-12-282023-03-28Vertex Pharmaceuticals IncorporatedModified urokinase-type plasminogen activator polypeptides and methods of use
WO2024015529A2 (en)2022-07-142024-01-18Jazz Pharmaceuticals Ireland Ltd.Combination therapies involving l-asparaginase
US12441992B2 (en)2021-06-032025-10-14Jazz Pharmaceuticals Ii SasMethod of treating AML with PEGylated l-asparaginase

Families Citing this family (638)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US6168778B1 (en)1990-06-112001-01-02Nexstar Pharmaceuticals, Inc.Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US6395888B1 (en)*1996-02-012002-05-28Gilead Sciences, Inc.High affinity nucleic acid ligands of complement system proteins
US6011020A (en)*1990-06-112000-01-04Nexstar Pharmaceuticals, Inc.Nucleic acid ligand complexes
US6465188B1 (en)1990-06-112002-10-15Gilead Sciences, Inc.Nucleic acid ligand complexes
US6147204A (en)*1990-06-112000-11-14Nexstar Pharmaceuticals, Inc.Nucleic acid ligand complexes
US6191105B1 (en)1993-05-102001-02-20Protein Delivery, Inc.Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
KR100361933B1 (en)*1993-09-082003-02-14라 졸라 파마슈티칼 컴파니 Chemically defined nonpolymeric bonds form the platform molecule and its conjugate
US5919455A (en)1993-10-271999-07-06Enzon, Inc.Non-antigenic branched polymer conjugates
US6057287A (en)1994-01-112000-05-02Dyax Corp.Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5545553A (en)*1994-09-261996-08-13The Rockefeller UniversityGlycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5859228A (en)*1995-05-041999-01-12Nexstar Pharmaceuticals, Inc.Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US8071737B2 (en)1995-05-042011-12-06Glead Sciences, Inc.Nucleic acid ligand complexes
ES2093593T1 (en)*1995-05-051997-01-01Hoffmann La Roche RECOMBINANT OBESE PROTEINS (OB).
US6229002B1 (en)1995-06-072001-05-08Nexstar Pharmaceuticlas, Inc.Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6833408B2 (en)1995-12-182004-12-21Cohesion Technologies, Inc.Methods for tissue repair using adhesive materials
DK0876165T3 (en)1995-12-182007-08-06Angiotech Biomaterials Corp Crosslinked polymer compositions and methods for their preparation
US6025324A (en)*1996-05-152000-02-15Hoffmann-La Roche Inc.Pegylated obese (ob) protein compositions
TW517067B (en)*1996-05-312003-01-11Hoffmann La RocheInterferon conjugates
AU4648697A (en)*1996-09-231998-04-14Chandrashekar PathakMethods and devices for preparing protein concentrates
US8003705B2 (en)*1996-09-232011-08-23Incept LlcBiocompatible hydrogels made with small molecule precursors
US6214966B1 (en)*1996-09-262001-04-10Shearwater CorporationSoluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6056973A (en)*1996-10-112000-05-02Sequus Pharmaceuticals, Inc.Therapeutic liposome composition and method of preparation
US6426335B1 (en)1997-10-172002-07-30Gilead Sciences, Inc.Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6051698A (en)*1997-06-062000-04-18Janjic; NebojsaVascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6258351B1 (en)1996-11-062001-07-10Shearwater CorporationDelivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US6743248B2 (en)1996-12-182004-06-01Neomend, Inc.Pretreatment method for enhancing tissue adhesion
US20030191496A1 (en)*1997-03-122003-10-09Neomend, Inc.Vascular sealing device with microwave antenna
US6371975B2 (en)1998-11-062002-04-16Neomend, Inc.Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
US20040176801A1 (en)*1997-03-122004-09-09Neomend, Inc.Pretreatment method for enhancing tissue adhesion
AU7121198A (en)*1997-04-181998-11-13California Institute Of TechnologyMultifunctional polymeric tissue coatings
EP1002064B1 (en)*1997-06-252007-10-10Novozymes A/SA modified polypeptide
US6284246B1 (en)1997-07-302001-09-04The Procter & Gamble Co.Modified polypeptides with high activity and reduced allergenicity
US6583251B1 (en)*1997-09-082003-06-24Emory UniversityModular cytomimetic biomaterials, transport studies, preparation and utilization thereof
WO1999013894A2 (en)*1997-09-181999-03-25F. Hoffmann-La Roche AgUse of ifn-alpha and amantadine for the treatment of chronic hepatitis c
EP0922446A1 (en)*1997-12-031999-06-16Applied Research Systems Ars Holding N.V.Solution-phase site-specific preparation of GRF-PEG conjugates
AR014621A1 (en)*1997-12-122001-03-28Macromed Inc A POLY (ETHYLENE GLYCOL) IN THE FORM OF A STAR, HETEROFUNCTIONAL, BIOCOMPATIBLE, METHOD FOR OBTAINING AND METHOD TO CONJUG WITH A PROTEIN
DK1411075T3 (en)1998-03-122008-10-27Nektar Therapeutics Al Corp Process for Preparation of Polymer Conjugates
SI1075281T1 (en)1998-04-282005-02-28Applied Research Systems Ars Holding N.V.Polyol-ifn-beta conjugates
CA2330448A1 (en)1998-04-281999-11-04Applied Research Systems Ars Holding N.V.Peg-lhrh analog conjugates
US7953788B2 (en)2001-09-292011-05-31Siebel Systems, Inc.System and method for queuing data for an application server
EP1588717B1 (en)*1998-04-282008-07-02Laboratoires Serono SAPEG-LHRH analog conjugates
US6258782B1 (en)1998-05-202001-07-10Trimeris, Inc.Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en)*1998-05-202003-12-02Trimeris, Inc.Hybrid polypeptides with enhanced pharmacokinetic properties
IL139786A0 (en)*1998-06-082002-02-10Hoffmann La RocheUse of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6783965B1 (en)*2000-02-102004-08-31Mountain View Pharmaceuticals, Inc.Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP1588716B1 (en)*1998-08-062011-02-16Mountain View Pharmaceuticals, Inc.Peg-urate oxidase conjugates and use thereof
US6632457B1 (en)1998-08-142003-10-14Incept LlcComposite hydrogel drug delivery systems
US6703381B1 (en)*1998-08-142004-03-09Nobex CorporationMethods for delivery therapeutic compounds across the blood-brain barrier
JP4860817B2 (en)*1998-08-262012-01-25ネオメンド、インク. Compositions, systems and methods for in situ creation of chemically cross-linked mechanical barriers or coating structures
US6458147B1 (en)1998-11-062002-10-01Neomend, Inc.Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
US6994686B2 (en)1998-08-262006-02-07Neomend, Inc.Systems for applying cross-linked mechanical barriers
JP2002526430A (en)1998-09-222002-08-20ザ、プロクター、エンド、ギャンブル、カンパニー Personal care compositions containing active proteins associated with a water-insoluble substrate
US7279001B2 (en)*1998-11-062007-10-09Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
US6899889B1 (en)*1998-11-062005-05-31Neomend, Inc.Biocompatible material composition adaptable to diverse therapeutic indications
US6830756B2 (en)*1998-11-062004-12-14Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
US6949114B2 (en)1998-11-062005-09-27Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
AU2707500A (en)1998-12-042000-06-26Incept LlcBiocompatible crosslinked polymers
US6458953B1 (en)*1998-12-092002-10-01La Jolla Pharmaceutical CompanyValency platform molecules comprising carbamate linkages
DK1181323T3 (en)1999-02-012011-10-17Eidgenoess Tech Hochschule Biomaterials formed by nucleophilic addition reaction with conjugated unsaturated groups
US6958212B1 (en)*1999-02-012005-10-25Eidgenossische Technische Hochschule ZurichConjugate addition reactions for the controlled delivery of pharmaceutically active compounds
JP4647792B2 (en)*1999-04-282011-03-09イジュノシッヒ テクニッヒ ホッフシューラ チューリッヒ Polyionic coatings in analytical and sensing devices
JP2003501412A (en)*1999-06-082003-01-14ラ ホヤ ファーマシューティカル カンパニー Valency platform molecules with aminooxy groups
US7169889B1 (en)1999-06-192007-01-30Biocon LimitedInsulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6309633B1 (en)1999-06-192001-10-30Nobex CorporationAmphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
CZ299516B6 (en)*1999-07-022008-08-20F. Hoffmann-La Roche AgErythropoietin glycoprotein conjugate, process for its preparation and use and pharmaceutical composition containing thereof
JO2291B1 (en)1999-07-022005-09-12اف . هوفمان لاروش ايه جيErythopintin derivatives
US6380405B1 (en)1999-09-132002-04-30Nobex CorporationTaxane prodrugs
US6541508B2 (en)*1999-09-132003-04-01Nobex CorporationTaxane prodrugs
US6713454B1 (en)1999-09-132004-03-30Nobex CorporationProdrugs of etoposide and etoposide analogs
US6303119B1 (en)1999-09-222001-10-16The Procter & Gamble CompanyPersonal care compositions containing subtilisin enzymes bound to water insoluble substrates
DE60032255T2 (en)*1999-10-042007-06-28Nektar Therapeutics Al, Corp., Huntsville POLYMER-STABILIZED NEUROPEPTIDES
US7074878B1 (en)*1999-12-102006-07-11Harris J MiltonHydrolytically degradable polymers and hydrogels made therefrom
US6348558B1 (en)1999-12-102002-02-19Shearwater CorporationHydrolytically degradable polymers and hydrogels made therefrom
US6638906B1 (en)1999-12-132003-10-28Nobex CorporationAmphiphilic polymers and polypeptide conjugates comprising same
EP2070968A3 (en)1999-12-222013-07-24Nektar TherapeuticsMethod for the Preparation of 1-Benzotriazolyl Carbonate Esters of Poly(ethylene glycol)
JP4593048B2 (en)1999-12-242010-12-08協和発酵キリン株式会社 Branched polyalkylene glycols
ES2327606T3 (en)2000-01-102009-11-02Maxygen Holdings Ltd CONJUGATES OF G-CSF.
WO2001058935A2 (en)2000-02-112001-08-16Maxygen ApsFACTOR VII OR VIIa-LIKE MOLECULES
WO2001062299A2 (en)2000-02-282001-08-30Shearwater CorporationWater-soluble polymer conjugates of artelinic acid
US6756037B2 (en)2000-03-312004-06-29Enzon, Inc.Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6777387B2 (en)2000-03-312004-08-17Enzon Pharmaceuticals, Inc.Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
CA2406343A1 (en)2000-04-132001-10-25Emory UniversityAntithrombogenic membrane mimetic compositions and methods
US7291673B2 (en)*2000-06-022007-11-06Eidgenossiche Technische Hochschule ZurichConjugate addition reactions for the controlled delivery of pharmaceutically active compounds
EP1292337A2 (en)*2000-06-082003-03-19La Jolla PharmaceuticalMultivalent platform molecules comprising high molecular weight polyethylene oxide
AU2001273387A1 (en)*2000-07-122002-01-21Gryphon Therapeutics, Inc.Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
JP2004512062A (en)2000-07-282004-04-22エモリー ユニバーシテイ Biological components consisting of artificial membranes
US7118737B2 (en)2000-09-082006-10-10Amylin Pharmaceuticals, Inc.Polymer-modified synthetic proteins
WO2002019963A2 (en)*2000-09-082002-03-14Gryphon Therapeutics, Inc.Synthetic erythropoiesis stimulating proteins
WO2002026265A2 (en)2000-09-292002-04-04Schering CorporationPegylated interleukin-10
WO2002055185A2 (en)*2000-10-192002-07-18Eidgenoess Tech HochschuleBlock copolymers for multifunctional self-assembled systems
US7053150B2 (en)*2000-12-182006-05-30Nektar Therapeutics Al, CorporationSegmented polymers and their conjugates
TW593427B (en)*2000-12-182004-06-21Nektar Therapeutics Al CorpSynthesis of high molecular weight non-peptidic polymer derivatives
AU2002235375A1 (en)2001-01-122002-07-24Emory UniversityGlycopolymers and free radical polymerization methods
TWI246524B (en)2001-01-192006-01-01Shearwater CorpMulti-arm block copolymers as drug delivery vehicles
US7265186B2 (en)*2001-01-192007-09-04Nektar Therapeutics Al, CorporationMulti-arm block copolymers as drug delivery vehicles
CA2436623C (en)*2001-01-302011-08-02Kyowa Hakko Kogyo Co., Ltd.Branched polyalkylene glycols
US6867183B2 (en)2001-02-152005-03-15Nobex CorporationPharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en)2001-02-152006-06-13Nobex CorporationMethods of treating diabetes mellitus
YU48703A (en)2001-02-272006-05-25Maxygen ApsNew interferon beta-like molecules
US20030044468A1 (en)*2001-03-202003-03-06Francesco CellesiTwo-phase processing of thermosensitive polymers for use as biomaterials
US6828297B2 (en)2001-06-042004-12-07Nobex CorporationMixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en)2001-06-042004-03-30Nobex CorporationMixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en)2001-06-042010-05-11Biocon LimitedCalcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en)2001-06-042004-12-07Nobex CorporationMixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en)2001-06-042005-02-22Nobex CorporationMixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20040077835A1 (en)*2001-07-122004-04-22Robin OffordChemokine receptor modulators, production and use
US7125558B2 (en)2001-08-222006-10-24Bioartificial Gel Technologies Inc,Process for the preparation of activated polyethylene glycols
KR100761652B1 (en)*2001-08-252007-10-04동아제약주식회사 Various polymer derivatives and conjugates that bind to proteins or peptides
US7196059B2 (en)2001-09-072007-03-27Biocon LimitedPharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en)*2001-09-072007-01-23Biocon LimitedInsulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en)2001-09-072005-07-05Nobex CorporationMethods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en)*2001-09-072007-12-25Biocon LimitedInsulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en)*2001-09-072006-04-18Nobex CorporationPharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US6770625B2 (en)2001-09-072004-08-03Nobex CorporationPharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US6908963B2 (en)2001-10-092005-06-21Nektar Therapeutics Al, CorporationThioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
US7696163B2 (en)2001-10-102010-04-13Novo Nordisk A/SErythropoietin: remodeling and glycoconjugation of erythropoietin
EP2292271A3 (en)2001-10-102011-09-14BioGeneriX AGRemodelling and glycoconjugation of an antibody
US7179617B2 (en)*2001-10-102007-02-20Neose Technologies, Inc.Factor IX: remolding and glycoconjugation of Factor IX
US7795210B2 (en)2001-10-102010-09-14Novo Nordisk A/SProtein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en)*2001-10-102011-08-30Novo Nordisk A/SFactor VII: remodeling and glycoconjugation of Factor VII
US7214660B2 (en)2001-10-102007-05-08Neose Technologies, Inc.Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en)2001-10-102007-02-06Neose Technologies, Inc.Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en)2001-11-282007-01-02Neose Technologies, Inc.Factor VIII remodeling and glycoconjugation of Factor VIII
EP2939696B1 (en)2001-10-182016-03-09Nektar TherapeuticsPolymer conjugates of opioid antagonists
AU2002352524B2 (en)2001-11-072007-10-04Nektar TherapeuticsBranched polymers and their conjugates
JP4663233B2 (en)*2001-11-092011-04-06エンゾン,インコーポレーテッド Polymeric thiol-linked prodrugs utilizing benzyl elimination systems
US20030171285A1 (en)*2001-11-202003-09-11Finn Rory F.Chemically-modified human growth hormone conjugates
US7473680B2 (en)2001-11-282009-01-06Neose Technologies, Inc.Remodeling and glycoconjugation of peptides
DE60323936D1 (en)2002-01-142008-11-20Gen Hospital Corp BIOABEAABLE POLYCETALES, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE
US7144978B2 (en)*2002-01-152006-12-05Pan Asia Bio Co., Ltd.Multidrop tree branching functional polyethylene glycol, methods of preparing and using same
CN1176137C (en)*2002-01-152004-11-17泛亚生物技术有限公司Multi-arm fork type functional polyethylene glycol preparation method and its application in medicine
ES2291613T3 (en)2002-01-162008-03-01Biocompatibles Uk Limited CONJUGATES OF POLYMERS.
GEP20074024B (en)2002-01-182007-01-10Biogen Idec IncPolyalkylene glycol comprising a radical for conjugation of biologically active compound
AU2003216379A1 (en)*2002-02-222003-09-09Control Delivery Systems, Inc.Method for treating otic disorders
JP4284412B2 (en)*2002-03-012009-06-24独立行政法人産業技術総合研究所 Cell and liposome immobilization body and immobilization method thereof
US20030179692A1 (en)*2002-03-192003-09-25Yoshitaka OhotomoStorage medium
WO2003078461A1 (en)*2002-03-202003-09-25Biopolymed Inc.Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
US8282912B2 (en)*2002-03-222012-10-09Kuros Biosurgery, AGCompositions for tissue augmentation
ITMI20020951A1 (en)*2002-05-062003-11-06Univ Degli Studi Trieste MULTIFUNCTIONAL DERIVATIVES OF POLYETHYLENGLICLE THEIR PREPARATION AND USE
ATE518885T1 (en)*2002-05-282011-08-15Ucb Pharma Sa PEG POSITION ISOMER OF AN ANTIBODY TO TNFALPHA (CDP870)
US7153829B2 (en)2002-06-072006-12-26Dyax Corp.Kallikrein-inhibitor therapies
DE60333758D1 (en)2002-06-072010-09-23Dyax Corp Prevention and reduction of ischemia
WO2003105768A2 (en)2002-06-132003-12-24Nobex CorporationMethods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
DE60336555D1 (en)2002-06-212011-05-12Novo Nordisk Healthcare Ag PEGYLATED GLYCO FORMS OF FACTOR VII
DK1517710T3 (en)2002-06-212011-07-18Novo Nordisk Healthcare Ag Pegylated factor VII glycoforms
ES2254725T3 (en)*2002-06-292006-06-16Aquanova German Solubilisate Technologies (Agt) Gmbh CONCENTRATES OF ISOFLAVONES AND METHODS FOR PREPARATION.
US7981862B2 (en)2003-08-192011-07-19Biosurface Engineering Technologies, Inc.Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis
US7598224B2 (en)2002-08-202009-10-06Biosurface Engineering Technologies, Inc.Dual chain synthetic heparin-binding growth factor analogs
US8227411B2 (en)*2002-08-202012-07-24BioSurface Engineering Technologies, IncleFGF growth factor analogs
US7166574B2 (en)2002-08-202007-01-23Biosurface Engineering Technologies, Inc.Synthetic heparin-binding growth factor analogs
AU2003276844A1 (en)*2002-08-282004-03-19Pharmacia CorporationFormulations of modified antibodies and methods of making the same
WO2004019861A2 (en)*2002-08-282004-03-11Pharmacia CorporationStable ph optimized formulation of a modified antibody
AU2003270118A1 (en)*2002-08-302004-03-19F. Hoffmann-La Roche AgScatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
EP1545623B1 (en)*2002-09-272007-05-09F. Hoffmann-La Roche AgConjugates of insulin-like growth factor binding protein-4 and poly (ethylene glycol)
US20040062748A1 (en)*2002-09-302004-04-01Mountain View Pharmaceuticals, Inc.Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en)*2002-09-302012-03-06Mountain View Pharmaceuticals, Inc.Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
TWI281864B (en)*2002-11-202007-06-01Pharmacia CorpN-terminally monopegylated human growth hormone conjugates and process for their preparation
US8853376B2 (en)2002-11-212014-10-07Archemix LlcStabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
SG159387A1 (en)2002-11-262010-03-30Biocon Ltd InModified natriuretic compounds, conjugates, and uses thereof
US7648962B2 (en)*2002-11-262010-01-19Biocon LimitedNatriuretic compounds, conjugates, and uses thereof
EP1628618A4 (en)*2002-12-262009-09-09Mountain View PharmaceuticalsPolymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
WO2004060299A2 (en)*2002-12-262004-07-22Mountain View Pharmaceuticals, Inc.Polymer conjugates of interferon-beta with enhanced biological potency
US8034900B2 (en)*2002-12-302011-10-11Amylin Pharmaceuticals, Inc.Water-soluble thioester and selenoester compounds and methods for making and using the same
US7329721B2 (en)2002-12-312008-02-12Nektar Therapeutics Al, CorporationMaleamic acid polymer derivatives and their bioconjugates
ATE444984T1 (en)*2002-12-312009-10-15Nektar Therapeutics Al Corp HYDROLYSIS-STABLE POLYMERS CONTAINING MALEIMIDE END GROUPS
US7432331B2 (en)*2002-12-312008-10-07Nektar Therapeutics Al, CorporationHydrolytically stable maleimide-terminated polymers
CN1744918A (en)*2002-12-312006-03-08尼克塔治疗亚拉巴马公司Polymeric reagents comprising a ketone or a related functional group
US20050130892A1 (en)*2003-03-072005-06-16Xencor, Inc.BAFF variants and methods thereof
US20060014248A1 (en)*2003-01-062006-01-19Xencor, Inc.TNF super family members with altered immunogenicity
US20050221443A1 (en)*2003-01-062005-10-06Xencor, Inc.Tumor necrosis factor super family agonists
AU2004204136B2 (en)*2003-01-062008-10-09Nektar TherapeuticsThiol-selective water-soluble polmer derivatives
US7553930B2 (en)*2003-01-062009-06-30Xencor, Inc.BAFF variants and methods thereof
GB0301014D0 (en)*2003-01-162003-02-19Biocompatibles LtdConjugation reactions
BRPI0407511A (en)*2003-02-192006-02-14Pharmacia Corp activated polyethylene glycol esters
SI1596887T1 (en)*2003-02-262022-05-31Nektar TherapeuticsPolymer-factor viii moiety conjugates
ES2420581T3 (en)*2003-03-142013-08-26Biogenerix Gmbh Branched water soluble polymers and their conjugates
EP1610825A2 (en)*2003-03-312006-01-04Xencor, Inc.Methods for rational pegylation of proteins
US7610156B2 (en)2003-03-312009-10-27Xencor, Inc.Methods for rational pegylation of proteins
US7642340B2 (en)2003-03-312010-01-05Xencor, Inc.PEGylated TNF-α variant proteins
US7691603B2 (en)*2003-04-092010-04-06Novo Nordisk A/SIntracellular formation of peptide conjugates
US8791070B2 (en)2003-04-092014-07-29Novo Nordisk A/SGlycopegylated factor IX
EP2338333B1 (en)2003-04-092017-09-06ratiopharm GmbHGlycopegylation methods and proteins/peptides produced by the methods
TW200510454A (en)2003-04-152005-03-16Smithkline Beecham CorpConjugates comprising human IL-18 and substitution mutants thereof
CA2524936A1 (en)2003-05-092004-12-02Neose Technologies, Inc.Compositions and methods for the preparation of human growth hormone glycosylation mutants
PL1656410T3 (en)2003-07-222010-08-31Nektar TherapeuticsMethod for preparing functionalized polymers from polymer alcohols
US9005625B2 (en)2003-07-252015-04-14Novo Nordisk A/SAntibody toxin conjugates
EP1653996A2 (en)*2003-08-082006-05-10Novo Nordisk Health Care AGUse of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
NZ546088A (en)2003-08-272009-10-30Ophthotech CorpCombination therapy for the treatment of ocular neovascular disorders using a PDGF antagonist and a VEGF antagonist
JP4739207B2 (en)*2003-08-292011-08-03ダイアックス コーポレーション PolyPEGylated protease inhibitors
JP4890253B2 (en)2003-10-092012-03-07アンブレツクス・インコーポレイテツド Azide or acetylene-terminated water-soluble polymer
WO2005035564A2 (en)2003-10-102005-04-21Xencor, Inc.Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
EP1673387B1 (en)2003-10-102010-09-15Novo Nordisk A/SIl-21 derivatives
EP2633866A3 (en)2003-10-172013-12-18Novo Nordisk A/SCombination therapy
US20050214250A1 (en)2003-11-062005-09-29Harris J MMethod of preparing carboxylic acid functionalized polymers
US20080305992A1 (en)2003-11-242008-12-11Neose Technologies, Inc.Glycopegylated erythropoietin
MXPA06005732A (en)*2003-11-242006-08-17Neose Technologies IncGlycopegylated erythropoietin.
WO2005072371A2 (en)*2004-01-262005-08-11Neose Technologies, Inc.Branched polymeric sugars and nucleotides thereof
US8633157B2 (en)2003-11-242014-01-21Novo Nordisk A/SGlycopegylated erythropoietin
WO2005056636A2 (en)2003-12-032005-06-23Nektar Therapeutics Al, CorporationMethod of preparing maleimide functionalized polymers
US7956032B2 (en)*2003-12-032011-06-07Novo Nordisk A/SGlycopegylated granulocyte colony stimulating factor
ES2422187T3 (en)*2003-12-032013-09-09Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
WO2005055950A2 (en)*2003-12-032005-06-23Neose Technologies, Inc.Glycopegylated factor ix
US20080318850A1 (en)*2003-12-032008-12-25Neose Technologies, Inc.Glycopegylated Factor Ix
US20060040856A1 (en)*2003-12-032006-02-23Neose Technologies, Inc.Glycopegylated factor IX
ES2817799T3 (en)2003-12-162021-04-08Nektar Therapeutics PEGylated naloxol monodisperse compositions
US20060182692A1 (en)2003-12-162006-08-17Fishburn C SChemically modified small molecules
AU2004298424A1 (en)2003-12-182005-06-30Novo Nordisk A/SNovel GLP-1 compounds
GB0329825D0 (en)*2003-12-232004-01-28Celltech R&D LtdBiological products
ES2560657T3 (en)*2004-01-082016-02-22Ratiopharm Gmbh O-linked glycosylation of G-CSF peptides
US7414028B1 (en)*2004-02-042008-08-19Biosurface Engineering Technologies, Inc.Growth factor analogs
US20080227696A1 (en)*2005-02-222008-09-18Biosurface Engineering Technologies, Inc.Single branch heparin-binding growth factor analogs
US7528105B1 (en)2004-02-102009-05-05Biosurface Engineering TechnologiesHeterodimeric chain synthetic heparin-binding growth factor analogs
US7671012B2 (en)2004-02-102010-03-02Biosurface Engineering Technologies, Inc.Formulations and methods for delivery of growth factor analogs
US20060024347A1 (en)*2004-02-102006-02-02Biosurface Engineering Technologies, Inc.Bioactive peptide coatings
US6887952B1 (en)*2004-02-122005-05-03Biosite, Inc.N-aryl-carbamic acid ester-derived and valeric acid ester-derived cross-linkers and conjugates, and methods for their synthesis and use
US7803931B2 (en)2004-02-122010-09-28Archemix Corp.Aptamer therapeutics useful in the treatment of complement-related disorders
CA2555583A1 (en)*2004-02-202005-09-09Biosurface Engineering Technologies, Inc.Positive modulator of bone morphogenic protein-2
US7833978B2 (en)2004-02-202010-11-16Emory UniversityThrombomodulin derivatives and conjugates
US7351787B2 (en)*2004-03-052008-04-01Bioartificial Gel Technologies, Inc.Process for the preparation of activated polyethylene glycols
EP1725262B1 (en)*2004-03-152021-05-26Nektar TherapeuticsPolymer-based compositions and conjugates of hiv entry inhibitors
EP1735340A2 (en)*2004-03-172006-12-27Eli Lilly And CompanyGlycol linked fgf-21 compounds
WO2005090395A2 (en)*2004-03-172005-09-29Anticancer, Inc.Methods for increasing protein polyethylene glycol (peg) conjugation
US7824672B2 (en)2004-03-262010-11-02Emory UniversityMethod for coating living cells
JP2008505853A (en)*2004-04-132008-02-28クインテセンス バイオサイエンシーズ インコーポレーティッド Non-natural ribonuclease complex as a cytotoxic agent
WO2005108463A2 (en)2004-05-032005-11-17Nektar Therapeutics Al, CorporationBranched polyethylen glycol derivates comprising an acetal or ketal branching point
US9085659B2 (en)*2004-05-032015-07-21Nektar TherapeuticsPolymer derivatives comprising an imide branching point
CA2568388A1 (en)*2004-06-082005-12-29Alza CorporationPreparation of macromolecular conjugates by four-component condensation reaction
WO2006010143A2 (en)2004-07-132006-01-26Neose Technologies, Inc.Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
PL2626368T3 (en)2004-07-192017-06-30Biocon LimitedInsulin-oligomer conjugates, formulations and uses thereof
US20060040377A1 (en)*2004-08-172006-02-23Biocept, Inc.Protein microarrays
EP1794588A2 (en)*2004-09-092007-06-13Biosite IncorporatedMethods and compositions for measuring canine bnp and uses thereof
WO2006031811A2 (en)2004-09-102006-03-23Neose Technologies, Inc.Glycopegylated interferon alpha
EP1799713B1 (en)2004-09-232014-11-05VasGene Therapeutics, Inc.Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7235530B2 (en)2004-09-272007-06-26Dyax CorporationKallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP3061461A1 (en)2004-10-292016-08-31ratiopharm GmbHRemodeling and glycopegylation of fibroblast growth factor (fgf)
CN101111267B (en)2004-12-212012-12-05尼克塔治疗公司Stabilized polymeric thiol reagents
EP1674113A1 (en)2004-12-222006-06-28F. Hoffmann-La Roche AgConjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
EP1828224B1 (en)2004-12-222016-04-06Ambrx, Inc.Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
MX2007008229A (en)2005-01-102007-09-11Neose Technologies IncGlycopegylated granulocyte colony stimulating factor.
US7879979B2 (en)*2005-01-212011-02-01Alere InternationalArginine analogs, and methods for their synthesis and use
EP1683573B1 (en)*2005-01-252009-08-05Varian B.V.Chromatography columns
US7365127B2 (en)*2005-02-042008-04-29Enzon Pharmaceuticals, Inc.Process for the preparation of polymer conjugates
WO2006086510A2 (en)*2005-02-092006-08-17Tyco Healthcare Group LpSynthetic sealants
EP1857462B9 (en)2005-02-182013-02-13Nof CorporationPolyoxyalkylene derivative
US20060233740A1 (en)*2005-03-232006-10-19Bossard Mary JConjugates of an hGH moiety and a polymer
WO2006105426A2 (en)*2005-03-302006-10-05Neose Technologies, Inc.Manufacturing process for the production of peptides grown in insect cell lines
US20060222596A1 (en)2005-04-012006-10-05Trivascular, Inc.Non-degradable, low swelling, water soluble radiopaque hydrogel polymer
US20100092505A1 (en)2005-04-052010-04-15Elisabetta BianchiMethod for Shielding Functional Sites or Epitopes on Proteins
US9187546B2 (en)2005-04-082015-11-17Novo Nordisk A/SCompositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US8148123B2 (en)2005-04-112012-04-03Savient Pharmaceuticals, Inc.Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
AU2006235495B2 (en)2005-04-112012-04-12Horizon Therapeutics Usa, Inc.Variant forms of urate oxidase and use thereof
SG161248A1 (en)2005-04-112010-05-27Savient Pharmaceuticals IncA variant form of urate oxidase and use thereof
US20080159976A1 (en)*2005-04-112008-07-03Jacob HartmanMethods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP1885403B1 (en)2005-04-122013-05-08Nektar TherapeuticsPoly(ethyleneglycol) conjugates of Lysostaphin
US7833979B2 (en)*2005-04-222010-11-16Amgen Inc.Toxin peptide therapeutic agents
BRPI0609676A2 (en)2005-05-132011-10-18Lilly Co Eli compound of pegylated glp-1, and use thereof
US20090081122A1 (en)*2005-05-232009-03-26Universite De GeneveInjectable superparamagnetic nanoparticles for treatment by hyperthermia and use for forming an hyperthermic implant
WO2006127910A2 (en)2005-05-252006-11-30Neose Technologies, Inc.Glycopegylated erythropoietin formulations
US20080255026A1 (en)*2005-05-252008-10-16Glycopegylated Factor 1XGlycopegylated Factor Ix
EP2298829B1 (en)*2005-05-312017-09-20École Polytechnique Fédérale de Lausanne (EPFL)Triblock copolymers for cytoplasmic delivery of gene-based drugs
KR101304157B1 (en)2005-06-162013-09-06넥타르 테라퓨틱스Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
EP1898955A2 (en)*2005-06-172008-03-19Nektar Therapeutics AL, CorporationPolymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs
WO2006134173A2 (en)2005-06-172006-12-21Novo Nordisk Health Care AgSelective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
ATE524509T1 (en)2005-07-182011-09-15Nektar Therapeutics BRANCHED FUNCTIONALIZED POLYMERS USING BRANCHED POLYOLS AS CORE
EP1915412B1 (en)2005-07-192010-03-24Nektar TherapeuticsMethod for preparing polymer maleimides
PT1922350E (en)*2005-07-292015-03-09Nektar TherapeuticsMethods for preparing polymeric reagents
US8008453B2 (en)2005-08-122011-08-30Amgen Inc.Modified Fc molecules
US20090305967A1 (en)*2005-08-192009-12-10Novo Nordisk A/SGlycopegylated factor vii and factor viia
US20070105755A1 (en)2005-10-262007-05-10Neose Technologies, Inc.One pot desialylation and glycopegylation of therapeutic peptides
KR100664969B1 (en)*2005-08-262007-01-04아이디비켐(주) Manufacturing method of high purity methoxy polyethylene glycol and their derivatives
US20090048440A1 (en)2005-11-032009-02-19Neose Technologies, Inc.Nucleotide Sugar Purification Using Membranes
SI1954710T1 (en)*2005-11-082011-08-31Ambrx IncAccelerants for the modification of non-natural amino acids and non-natural amino acid polypeptides
CU23556A1 (en)*2005-11-302010-07-20Ct Ingenieria Genetica Biotech POLYMER STRUCTURE SIMILAR TO DENDRÍMERO FOR THE OBTAINING OF CONJUGATES OF PHARMACEUTICAL INTEREST
EP1968644B1 (en)2005-12-162012-06-27Nektar TherapeuticsPolymer conjugates of glp-1
US7743730B2 (en)*2005-12-212010-06-29Lam Research CorporationApparatus for an optimized plasma chamber grounded electrode assembly
US20070190127A1 (en)2005-12-302007-08-16Mingdong ZhouExtended release of neuregulin for improved cardiac function
JP5312050B2 (en)2006-02-212013-10-09ネクター セラピューティクス Split-type degradable polymers and composites produced therefrom
US7928058B2 (en)2006-02-222011-04-19Merck Sharp & Dohme Corp.Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
US7816484B2 (en)*2006-02-282010-10-19Dr. Reddy's Laboratories LimitedMethod for making polyethylene glycol carbonates
EP4159220A1 (en)*2006-03-082023-04-05Archemix LLCComplement binding aptamers and anti-c5 agents useful in the treatment of ocular disorders
AU2007227641B2 (en)2006-03-132012-11-29Liat MintzUse of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
US8795709B2 (en)2006-03-292014-08-05Incept LlcSuperabsorbent, freeze dried hydrogels for medical applications
ES2430323T3 (en)2006-03-302013-11-20Palatin Technologies, Inc. Cyclic natriuretic peptide constructs
US8580746B2 (en)*2006-03-302013-11-12Palatin Technologies, Inc.Amide linkage cyclic natriuretic peptide constructs
US7795221B2 (en)*2006-03-302010-09-14Palatin Technologies, Inc.Linear natriuretic peptide constructs
US9101670B2 (en)2006-04-072015-08-11Nektar TherapeuticsConjugates of an anti-TNF-α antibody
KR101288027B1 (en)*2006-04-122013-07-22새비언트 파마수티컬즈 인크.Purification of proteins with cationic surfactant
US8288339B2 (en)2006-04-202012-10-16Amgen Inc.GLP-1 compounds
NZ572252A (en)2006-04-212011-09-30Nektar TherapeuticsStereoselective reduction of a morphinone
US20080096819A1 (en)2006-05-022008-04-24Allozyne, Inc.Amino acid substituted molecules
US7632492B2 (en)2006-05-022009-12-15Allozyne, Inc.Modified human interferon-β polypeptides
MX2008014685A (en)2006-05-242008-11-27Novo Nordisk Healthcare AgFactor ix analogues having prolonged in vivo half life.
US7872068B2 (en)*2006-05-302011-01-18Incept LlcMaterials formable in situ within a medical device
US7820172B1 (en)2006-06-012010-10-26Biosurface Engineering Technologies, Inc.Laminin-derived multi-domain peptides
US8840882B2 (en)*2006-06-232014-09-23Quintessence Biosciences, Inc.Modified ribonucleases
US8008948B2 (en)*2006-07-062011-08-30Denso CorporationPeak voltage detector circuit and binarizing circuit including the same circuit
WO2008010991A2 (en)*2006-07-172008-01-24Quintessence Biosciences, Inc.Methods and compositions for the treatment of cancer
EP2044150B1 (en)2006-07-212014-01-15Nektar TherapeuticsPolymeric reagents comprising a terminal vinylic group and conjugates formed therefrom
WO2008011633A2 (en)2006-07-212008-01-24Neose Technologies, Inc.Glycosylation of peptides via o-linked glycosylation sequences
CL2007002502A1 (en)2006-08-312008-05-30Hoffmann La Roche VARIANTS OF THE SIMILAR GROWTH FACTOR TO HUMAN INSULIN-1 (IGF-1) PEGILATED IN LISIN; METHOD OF PRODUCTION; FUSION PROTEIN THAT UNDERSTANDS IT; AND ITS USE TO TREAT ALZHEIMER'S DISEASE.
ES2393373T3 (en)*2006-08-312012-12-20F. Hoffmann-La Roche Ag Method for the production of insulin-like growth factor-I
US8846624B2 (en)2006-09-112014-09-30Emory UniversityModified protein polymers
US7985783B2 (en)2006-09-212011-07-26The Regents Of The University Of CaliforniaAldehyde tags, uses thereof in site-specific protein modification
NZ597098A (en)2006-09-282013-05-31Merck Sharp & DohmeUse of pegylated il-10 to treat cancer
EP2054521A4 (en)2006-10-032012-12-19Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
WO2008060780A2 (en)2006-10-042008-05-22Novo Nordisk A/SGlycerol linked pegylated sugars and glycopeptides
WO2008051383A2 (en)*2006-10-192008-05-02Amgen Inc.Use of alcohol co-solvents to improve pegylation reaction yields
US7803769B2 (en)*2006-10-252010-09-28Amgen Inc.OSK1 peptide analogs and pharmaceutical compositions
US20080207487A1 (en)*2006-11-022008-08-28Neose Technologies, Inc.Manufacturing process for the production of polypeptides expressed in insect cell-lines
CN101583637B (en)*2006-11-072012-08-08帝斯曼知识产权资产管理有限公司 Carbamate, thiocarbamate, or urea containing biomolecular fragments
AU2007325838B2 (en)2006-11-222013-09-19Bristol-Myers Squibb CompanyTargeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
CN101583380B (en)2006-11-302013-07-10尼克塔治疗公司Method for preparing a polymer conjugate
US8685417B2 (en)*2006-12-202014-04-01Arkema, Inc.Polymer encapsulation and/or binding
CA2671676C (en)2006-12-272014-04-22Baxter Healthcare SaVon willebrand factor-and factor viii-polymer conjugates having a releasable linkage
CN101588819B (en)*2006-12-272012-11-21尼克塔治疗公司Factor ix moiety-polymer conjugates having a releaseable linkage
KR101160385B1 (en)2007-01-182012-07-10일라이 릴리 앤드 캄파니PEGYLATED Aß FAB
US20080254188A1 (en)*2007-02-012008-10-16National Research Council Of CanadaFormulations of lipophilic bioactive molecules
ATE516814T1 (en)2007-02-022011-08-15Bristol Myers Squibb Co 10FN3 DOMAIN FOR THE TREATMENT OF DISEASES ACCOMPANIED BY UNDESIRABLE ANGIOGENESIS
JP2010522583A (en)2007-02-272010-07-08トラスティーズ オブ タフツ カレッジ Silk organs made by tissue engineering
US20090227981A1 (en)*2007-03-052009-09-10Bennett Steven LLow-Swelling Biocompatible Hydrogels
US20090227689A1 (en)*2007-03-052009-09-10Bennett Steven LLow-Swelling Biocompatible Hydrogels
PL2144923T3 (en)2007-04-032013-12-31Biogenerix AgMethods of treatment using glycopegylated g-csf
WO2008125655A1 (en)2007-04-132008-10-23Kuros Biosurgery AgPolymeric tissue sealant
JP5591691B2 (en)*2007-05-222014-09-17アムジエン・インコーポレーテツド Compositions and methods for making biologically active fusion proteins
WO2009027844A2 (en)*2007-05-252009-03-05Celtic Pharma Management L.P.Crf conjugates with extended half-lives
CA2688431C (en)2007-05-292016-07-05Trustees Of Tufts CollegeMethod for silk fibroin gelation using sonication
CN101778859B (en)2007-06-122014-03-26诺和诺德公司Improved process for the production of nucleotide sugars
CL2008002053A1 (en)*2007-07-172009-05-22Hoffmann La Roche Method for the purification of a monopeglated erythropoietin (epompeg) which consists of providing a solution containing mono, poly and non-peglated erythropoietin and passing it through two steps of cation exchange chromatography and a method to produce epo mpeg that includes a purification method.
AR067536A1 (en)*2007-07-172009-10-14Hoffmann La Roche METHOD FOR OBTAINING A MONO-PEGILATED ERYTHROPOYETIN IN A SUBSTANTIALLY HOMOGENOUS FORM
US8067028B2 (en)*2007-08-132011-11-29Confluent Surgical Inc.Drug delivery device
CL2008002399A1 (en)*2007-08-162009-01-02Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
CA2707840A1 (en)2007-08-202009-02-26Allozyne, Inc.Amino acid substituted molecules
WO2009026334A2 (en)*2007-08-212009-02-26Genzyme CorporationTreatment with kallikrein inhibitors
US8207112B2 (en)2007-08-292012-06-26Biogenerix AgLiquid formulation of G-CSF conjugate
WO2009043027A2 (en)*2007-09-272009-04-02Serina Therapeutics, Inc.Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
US8697062B2 (en)*2007-10-082014-04-15Quintessence Biosciences, Inc.Compositions and methods for ribonuclease-based therapeutics
ES2664822T3 (en)2007-10-162018-04-23Biocon Limited A solid pharmaceutical composition orally administrable and a process thereof
MX2010004400A (en)2007-10-232010-05-20Nektar TherapeuticsHydroxyapatite-targeting multiarm polymers and conjugates made therefrom.
EP3042922B1 (en)2008-01-112017-07-19Serina Therapeutics, Inc.Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8101706B2 (en)2008-01-112012-01-24Serina Therapeutics, Inc.Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US7862538B2 (en)*2008-02-042011-01-04Incept LlcSurgical delivery system for medical sealant
CA2715465C (en)2008-02-272017-03-21Novo Nordisk A/SConjugated factor viii molecules
EP2274016B1 (en)*2008-04-032012-07-25F. Hoffmann-La Roche AGPegylated igf-i variants for use in the treatment of neuromuscular disorders
KR20100119899A (en)*2008-04-032010-11-11에프. 호프만-라 로슈 아게Pegylated insulin-like-growth-factor assay
MX2010011882A (en)*2008-04-302011-02-25Neutron RowUse of corticotropin-releasing factor for the treatment of cancer.
US20110135623A1 (en)*2008-05-162011-06-09Nektar TherapeuticsConjugates of a Cholinesterase Moiety and a Polymer
PE20091931A1 (en)2008-05-222009-12-31Bristol Myers Squibb Co MULTIVALENT FIBRONECTIN-BASED FRAME DOMAIN PROTEINS
KR101533757B1 (en)*2008-07-312015-07-03파마이센시아 코퍼레이션Peptide-polymer conjugates
WO2010014258A2 (en)*2008-08-012010-02-04Nektar Therapeutics Al, CorporationConjugates having a releasable linkage
AU2009282413B2 (en)2008-08-112014-07-17Nektar TherapeuticsMulti-arm polymeric alkanoate conjugates
EP2326351B1 (en)2008-08-192017-12-27Nektar TherapeuticsConjugates of small-interfering nucleic acids
EP2331139B1 (en)2008-09-112019-04-17Nektar TherapeuticsPolymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
EP2334333A1 (en)*2008-09-192011-06-22Nektar TherapeuticsPolymer conjugates of v681-like peptides
EP2334334A1 (en)2008-09-192011-06-22Nektar TherapeuticsPolymer conjugates of nesiritide peptides
EP2334337A1 (en)*2008-09-192011-06-22Nektar TherapeuticsPolymer conjugates of opioid growth factor peptides
EP2340045B1 (en)2008-09-192017-04-12Nektar TherapeuticsPolymer conjugates of protegrin peptides
US20110171164A1 (en)*2008-09-192011-07-14Nektar TherapeuticsPolymer conjugates of glp-2-like peptides
EP2341942A1 (en)*2008-09-192011-07-13Nektar TherapeuticsPolymer conjugates of therapeutic peptides
WO2010033204A2 (en)*2008-09-192010-03-25Nektar TherapeuticsPolymer conjugates of c-peptides
EP2340050A2 (en)*2008-09-192011-07-06Nektar TherapeuticsPolymer conjugates of aod-like peptides
US20110171312A1 (en)*2008-09-192011-07-14Nektar TherapeuticsModified therapeutic peptides, methods of their preparation and use
EP2344199A1 (en)*2008-09-192011-07-20Nektar TherapeuticsPolymer conjugates of thymosin alpha 1 peptides
WO2010033224A1 (en)*2008-09-192010-03-25Nektar TherapeuticsPolymer conjugates of kiss1 peptides
WO2010033218A1 (en)*2008-09-192010-03-25Nektar TherapeuticsPolymer conjugates of osteocalcin peptides
EP2340046A2 (en)*2008-09-192011-07-06Nektar TherapeuticsPolymer conjugates of ziconotide peptides
US8029782B2 (en)2008-10-012011-10-04Quintessence Biosciences, Inc.Therapeutic ribonucleases
TWI496582B (en)2008-11-242015-08-21必治妥美雅史谷比公司Bispecific egfr/igfir binding molecules
WO2010068432A1 (en)2008-11-252010-06-17Ecole Polytechnique Federale De Lausanne (Epfl)Block copolymers and uses thereof
HUE037936T2 (en)2008-12-172018-09-28Merck Sharp & DohmeMono- and di-peg il-10 production; and uses
CN102307594A (en)*2009-01-062012-01-04戴埃克斯有限公司Treatment of mucositis with kallikrein inhibitors
US20110318322A1 (en)2009-01-122011-12-29Nektar TherapeuticsConjugates of a Lysosomal Enzyme Moiety and a Water Soluble Polymer
JP5890182B2 (en)2009-02-122016-03-22インセプト エルエルシー Drug delivery with hydrogel plugs
EP2405758B1 (en)*2009-03-092016-04-27Molecular Express, Inc.Methods and compositions for liposomal formulation of antigens and uses thereof
JP5569787B2 (en)*2009-03-312014-08-13日油株式会社 Purification method of high molecular weight polyethylene glycol compound
CN102482340B (en)2009-04-062015-05-13诺沃—诺迪斯克有限公司Targeted delivery of factor viii proteins to platelets
US8067201B2 (en)*2009-04-172011-11-29Bristol-Myers Squibb CompanyMethods for protein refolding
CN101870728A (en)2009-04-232010-10-27派格生物医药(苏州)有限公司Novel Exendin variant and conjugate thereof
WO2010129510A2 (en)*2009-05-042010-11-11Incept. LlcBiomaterials for track and puncture closure
KR20180126103A (en)2009-06-092018-11-26프로롱 파마슈티컬스, 엘엘씨Hemoglobin compositions
EP2446260B1 (en)2009-06-252018-12-26Horizon Pharma Rheumatology LLCMethods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
WO2011035065A1 (en)2009-09-172011-03-24Nektar TherapeuticsMonoconjugated chitosans as delivery agents for small interfering nucleic acids
JP2013506058A (en)2009-09-282013-02-21タフツ ユニバーシティー/トラスティーズ オブ タフツ カレッジ Stretched silk egel fiber and method for producing the same
CA2778678A1 (en)2009-10-302011-05-05Cns Therapeutics, Inc.Improved neurturin molecules
US20110136727A1 (en)*2009-11-202011-06-09Sergei SvarovskyCompositions and methods for rapid selection of pathogen binding agents
JO2976B1 (en)2009-12-222016-03-15ايلي ليلي اند كومبانيOxyntomodulin peptide analogue ‎
AR079344A1 (en)2009-12-222012-01-18Lilly Co Eli PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
US20110152188A1 (en)*2009-12-232011-06-23Hanns-Christian MahlerPharmaceutical compositions of igf/i proteins
EP4011917A1 (en)2010-01-062022-06-15Takeda Pharmaceutical Company LimitedPlasma kallikrein binding proteins
EP2533813B1 (en)2010-02-112016-06-01F.Hoffmann-La Roche AgProtein conjugates for trypsin mediated pegylation by transamidation and methods
EP2536754A1 (en)2010-02-162012-12-26Novo Nordisk A/SFactor viii fusion protein
JP5914363B2 (en)2010-02-162016-05-11ノヴォ ノルディスク アー/エス Factor VIII molecule with reduced VWF binding
US8889193B2 (en)2010-02-252014-11-18The Johns Hopkins UniversitySustained delivery of therapeutic agents to an eye compartment
WO2011107591A1 (en)2010-03-052011-09-09RigshospitaletChimeric inhibitor molecules of complement activation
US8980253B2 (en)2010-04-262015-03-17Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
EP2563381B1 (en)2010-04-272017-08-09aTyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
CA2797271C (en)2010-04-282021-05-25Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
US9068177B2 (en)2010-04-292015-06-30Atyr Pharma, IncInnovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
JP6008838B2 (en)2010-04-292016-10-19エータイアー ファーマ, インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of asparaginyl tRNA synthetase
JP5991963B2 (en)2010-04-292016-09-14エータイアー ファーマ, インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of valyl tRNA synthetase
EP2566495B1 (en)2010-05-032017-03-01aTyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
EP2566496B1 (en)2010-05-032018-02-28aTyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
EP2566515B1 (en)2010-05-032017-08-02aTyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
CN102985103A (en)2010-05-042013-03-20Atyr医药公司Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
EP2569331A1 (en)2010-05-102013-03-20Perseid Therapeutics LLCPolypeptide inhibitors of vla4
WO2011143482A2 (en)2010-05-142011-11-17Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN103119055A (en)2010-05-172013-05-22塞比克斯公司Pegylated C-Peptide
WO2011146410A2 (en)2010-05-172011-11-24Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-trna synthetases
JP6023703B2 (en)2010-05-262016-11-09ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Fibronectin based scaffold proteins with improved stability
CA2800281C (en)2010-06-012021-01-12Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
US20130303799A1 (en)*2010-07-012013-11-14Santiago VaillardProcess for the preparation of poly(alkylene oxide) derivatives for modification of biologically active molecules and materials
CA2804416C (en)2010-07-122020-04-28Atyr Pharma, Inc.Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
AU2011293294B2 (en)2010-08-252016-03-24Pangu Biopharma LimitedInnovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
US10307372B2 (en)2010-09-102019-06-04The Johns Hopkins UniversityRapid diffusion of large polymeric nanoparticles in the mammalian brain
CN103118708B (en)2010-09-142015-08-26霍夫曼-拉罗奇有限公司For the method for the erythropoietin of purification Pegylation
US8961501B2 (en)2010-09-172015-02-24Incept, LlcMethod for applying flowable hydrogels to a cornea
RU2439091C1 (en)*2010-10-062012-01-10Общество С Ограниченной Ответственностью "Форт" (Ооо "Форт")Polyethylene glycol derivatives containing aromatic diazo group
JP5937092B2 (en)2010-10-192016-06-22トラスティーズ オブ タフツ カレッジ Silk fibroin-based microneedle and method for producing the same
WO2012054822A1 (en)2010-10-222012-04-26Nektar TherapeuticsPharmacologically active polymer-glp-1 conjugates
WO2012054861A1 (en)2010-10-222012-04-26Nektar TherapeuticsGlp-1 polymer conjugates having a releasable linkage
CA3144697A1 (en)2010-11-122012-05-18Nektar TherapeuticsConjugates of an il-2 moiety and a polymer
EP2657272B1 (en)*2010-12-212016-04-27NOF CorporationPurification method for carboxyl-containing polyoxyethylene derivative
US20130331443A1 (en)2010-12-222013-12-12Nektar TherapeuticsMulti-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en)2010-12-222021-01-19Nektar TherapeuticsMulti-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088506A1 (en)2010-12-232012-06-28Nektar TherapeuticsPolymer-semaxanib moiety conjugates
US10220020B2 (en)2010-12-232019-03-05Nektar TherapeuticsPolymer-des-ethyl sunitinib conjugates
WO2012088529A1 (en)2010-12-232012-06-28Nektar TherapeuticsPolymer-sunitinib conjugates
US8163869B1 (en)2010-12-272012-04-24Nof CorporationPurification method of carboxyl group-containing polyoxyethylene derivative
US8816055B2 (en)2011-01-062014-08-26Dyax Corp.Plasma kallikrein binding proteins
US8440309B2 (en)2011-01-312013-05-14Confluent Surgical, Inc.Crosslinked polymers with the crosslinker as therapeutic for sustained release
US9327037B2 (en)2011-02-082016-05-03The Johns Hopkins UniversityMucus penetrating gene carriers
CN103429256B (en)2011-03-022022-09-13诺和诺德保健股份有限公司Targeting of coagulation factors to TLT-1 on activated platelets
AP2013007173A0 (en)2011-03-162013-10-31Amgen IncPotent and selective inhibitors of NAV1.3 and NAV1.7
US10335519B2 (en)2011-04-202019-07-02Trustees Of Tufts CollegeDynamic silk coatings for implantable devices
US20140187488A1 (en)2011-05-172014-07-03Bristol-Myers Squibb CompanyMethods for maintaining pegylation of polypeptides
US20140088021A1 (en)2011-05-272014-03-27Nektar TherapeuticsWater-Soluble Polymer-Linked Binding Moiety and Drug Compounds
EA033472B1 (en)2011-06-172019-10-31Halozyme IncComposition for stabilization of hyaluronidase and use thereof
WO2013003593A1 (en)2011-06-282013-01-03Alternative Innovative Technologies LlcMethods of use of hsp70 for increased performance or hsp70 related disorders
KR20140054009A (en)2011-07-012014-05-08바이엘 인텔렉쳐 프로퍼티 게엠베하Relaxin fusion polypeptides and uses thereof
HUE029855T2 (en)2011-07-052017-04-28Bioasis Technologies IncP97-antibody conjugates
WO2013020079A2 (en)2011-08-042013-02-07Nektar TherapeuticsConjugates of an il-11 moiety and a polymer
WO2013033476A1 (en)*2011-08-302013-03-07Quanta Biodesign, Ltd.Branched discrette peg constructs
US10226417B2 (en)2011-09-162019-03-12Peter JarrettDrug delivery systems and applications
US8541368B2 (en)2011-09-232013-09-24Novo Nordisk A/SGlucagon analogues
US9937241B2 (en)2011-10-142018-04-10Alternative Innovative Technologies LlcDegradation resistant HSP70 formulations and uses thereof
CN104053670A (en)2011-10-312014-09-17百时美施贵宝公司Fibronectin binding domains with reduced immunogenicity
CA2855770A1 (en)2011-11-172013-05-23Cebix AbPegylated c-peptide
US9205150B2 (en)2011-12-052015-12-08Incept, LlcMedical organogel processes and compositions
RU2685867C2 (en)2011-12-152019-04-23Алтернатив Инновейтив Текнолоджиз ЛлцHybrid proteins and protein conjugates based on heat shock protein-70 (hsp70) and methods for use thereof (versions)
WO2013110028A1 (en)2012-01-192013-07-25The Johns Hopkins UniversityNanoparticle formulations with enhanced mucosal penetration
WO2013123432A2 (en)2012-02-162013-08-22Atyr Pharma, Inc.Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
EP2820150A1 (en)2012-03-012015-01-07Novo Nordisk A/SN-terminally modified oligopeptides and uses thereof
WO2013138338A2 (en)2012-03-122013-09-19Massachusetts Institute Of TechnologyMethods for treating tissue damage associated with ischemia with apoliporotein d
EP2825207B1 (en)2012-03-162020-08-19The Johns Hopkins UniversityNon-linear multiblock copolymer-drug conjugates for the delivery of active agents
US8962577B2 (en)2012-03-162015-02-24The Johns Hopkins UniversityControlled release formulations for the delivery of HIF-1 inhibitors
WO2013149219A2 (en)2012-03-302013-10-03Sorrento Therapeutics Inc.Fully human antibodies that bind to vegfr2
BR112014026442A8 (en)2012-05-012018-01-16Novo Nordisk As combination to achieve glycemic control, its use, and pharmaceutical composition.
JP6392209B2 (en)2012-05-042018-09-19ザ・ジョンズ・ホプキンス・ユニバーシティー Lipid-based drug carriers for rapid permeation through the mucus lining
US9533068B2 (en)*2012-05-042017-01-03The Johns Hopkins UniversityDrug loaded microfiber sutures for ophthalmic application
DK2849567T3 (en)2012-05-172022-06-20Extend Biosciences Inc CARRIERS FOR IMPROVED MEDICINE ADMINISTRATION
WO2013177187A2 (en)2012-05-222013-11-28Massachusetts Institute Of TechnologySynergistic tumor treatment with extended-pk il-2 and therapeutic agents
HK1204557A1 (en)2012-05-312015-11-27Sorrento Therapeutics, Inc.Antigen binding proteins that bind pd-l1
US9650331B2 (en)2012-06-182017-05-16Polytherics LimitedConjugation reagents
GB201210770D0 (en)2012-06-182012-08-01Polytherics LtdNovel conjugation reagents
CN109503714A (en)2012-06-212019-03-22索伦托治疗有限公司Antigen-binding proteins in conjunction with c-Met
EP2864358B1 (en)2012-06-222019-08-07Sorrento Therapeutics, Inc.Antigen binding proteins that bind ccr2
US10034945B2 (en)2012-07-132018-07-31Trustees Of Tufts CollegeSilk powder compaction for production of constructs with high mechanical strength and stiffness
US9932565B2 (en)2012-07-312018-04-03Bioasis Technologies, Inc.Dephosphorylated lysosomal storage disease proteins and methods of use thereof
SI3564258T1 (en)2012-09-132021-07-30Bristol-Myers Squibb CompanyFibronectin based scaffold domain proteins that bind to myostatin
CA2883833C (en)2012-10-112020-10-27Ascendis Pharma A/SHydrogel prodrugs
WO2014074218A1 (en)2012-11-122014-05-15Redwood Bioscience, Inc.Compounds and methods for producing a conjugate
US9310374B2 (en)2012-11-162016-04-12Redwood Bioscience, Inc.Hydrazinyl-indole compounds and methods for producing a conjugate
KR20150085064A (en)2012-11-162015-07-22더 리젠트스 오브 더 유니이버시티 오브 캘리포니아Pictet-spengler ligation for protein chemical modification
WO2014099984A1 (en)2012-12-202014-06-26Amgen Inc.Apj receptor agonists and uses thereof
DK2947111T3 (en)*2013-01-172018-05-07Xiamen Sinopeg Biotech Co Ltd MONOFUNCTIONAL BRANCHED POLYETHYLENE LYCOL AND BIORELATED SUBSTANCE MODIFIED BY SAME
WO2014120891A2 (en)2013-02-012014-08-07Bristol-Myers Squibb CompanyFibronectin based scaffold proteins
US9272075B2 (en)2013-02-042016-03-01W.L. Gore & Associates, Inc.Coating for substrate
AU2014211351B2 (en)2013-02-042017-04-13W. L. Gore & Associates, Inc.Coating for substrate
WO2014124006A1 (en)2013-02-052014-08-14The Johns Hopkins UniversityNanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
US10344060B2 (en)2013-03-122019-07-09Amgen Inc.Potent and selective inhibitors of Nav1.7
NZ711373A (en)2013-03-132020-07-31Bioasis Technologies IncFragments of p97 and uses thereof
WO2014152657A1 (en)2013-03-142014-09-25Alere San Diego, Inc.6-acetylmorphine analogs, and methods for their synthesis and use
US11376329B2 (en)2013-03-152022-07-05Trustees Of Tufts CollegeLow molecular weight silk compositions and stabilizing silk compositions
US9896513B2 (en)2013-03-152018-02-20Novo Nordisk A/SAntibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor
KR102774944B1 (en)2013-03-152025-02-27트러스티즈 오브 터프츠 칼리지Low molecular weight silk compositions and stabilizing silk compositions
RS59124B1 (en)2013-04-182019-09-30Novo Nordisk AsStable, protracted glp-1/glucagon receptor co-agonists for medical use
US9943568B2 (en)2013-04-182018-04-17Armo Biosciences, Inc.Methods of using pegylated interleukin-10 for treating cancer
US10285702B2 (en)2013-04-242019-05-14Trustees Of Tufts CollegeBioresorbable biopolymer anastomosis devices
CA3175360C (en)2013-05-312024-05-28Sorrento Therapeutics, Inc.Antigen binding proteins that bind pd-1
JP2016528879A (en)2013-06-172016-09-23アルモ・バイオサイエンシーズ・インコーポレイテッド Methods for assessing protein identity and stability
BR112016000546A2 (en)2013-07-122017-11-21Ophthotech Corp methods to treat or prevent eye conditions
WO2015013510A1 (en)2013-07-252015-01-29Ecole Polytechnique Federale De Lausanne EpflHigh aspect ratio nanofibril materials
WO2015023979A1 (en)*2013-08-162015-02-19Equip, LlcDiscrete peg constructs
US20150093399A1 (en)2013-08-282015-04-02Bioasis Technologies, Inc.Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015031316A1 (en)2013-08-302015-03-05Armo Biosciences, Inc.Methods of using interleukin-10 for treating diseases and disorders
PL3063275T3 (en)2013-10-312020-03-31Resolve Therapeutics, LlcTherapeutic nuclease-albumin fusions and methods
KR20160079114A (en)2013-11-112016-07-05아르모 바이오사이언시스 인코포레이티드Methods of using interleukin-10 for treating diseases and disorders
US9493413B2 (en)2013-11-272016-11-15Redwood Bioscience, Inc.Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EP3077008B1 (en)2013-12-062023-10-04Jie HanBioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
CU20140003A7 (en)*2014-01-082015-08-27Ct De Inmunología Molecular Biofarmacuba CONJUGATE UNDERSTANDING ERYTHROPOYETIN AND A RAMIFIED POLYMER STRUCTURE
WO2015127389A1 (en)2014-02-232015-08-27The Johns Hopkins UniversityHypotonic enema formulations and methods of use
US10428158B2 (en)2014-03-272019-10-01Dyax Corp.Compositions and methods for treatment of diabetic macular edema
MA39711A (en)2014-04-032015-10-08Nektar TherapeuticsConjugates of an il-15 moiety and a polymer
CN103980494B (en)*2014-04-212016-04-13国家纳米科学中心A kind of polypeptide polymer with anti-tumor activity and its preparation method and application
US10358636B2 (en)2014-05-142019-07-23Stealth Biologics, LlcDeimmunized lysostaphin and methods of use
WO2015187295A2 (en)2014-06-022015-12-10Armo Biosciences, Inc.Methods of lowering serum cholesterol
EP3151852A1 (en)2014-06-042017-04-12Novo Nordisk A/SGlp-1/glucagon receptor co-agonists for medical use
AU2015274574B2 (en)2014-06-102019-10-10Amgen Inc.Apelin polypeptides
US20170224777A1 (en)2014-08-122017-08-10Massachusetts Institute Of TechnologySynergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
US10166273B2 (en)2014-08-122019-01-01The Board Of Trustees Of The Leland Stanford Junior UniversitySynergistic tumor treatment with antibodies targeting PD-1, PD-L1 or CTLA4 and integrin-binding-Fc-fusion protein
WO2016025215A1 (en)2014-08-132016-02-18The Johns Hopkins UniversityGlucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization
AU2015305894A1 (en)2014-08-222017-04-06Sorrento Therapeutics, Inc.Antigen binding proteins that bind CXCR3
JP2017536098A (en)2014-10-142017-12-07アルモ・バイオサイエンシーズ・インコーポレイテッド Interleukin-15 composition and use thereof
US9789197B2 (en)2014-10-222017-10-17Extend Biosciences, Inc.RNAi vitamin D conjugates
WO2016065042A1 (en)2014-10-222016-04-28Extend Biosciences, Inc.Therapeutic vitamin d conjugates
WO2016065052A1 (en)2014-10-222016-04-28Extend Biosciences, Inc.Insulin vitamin d conjugates
CN107106655A (en)2014-10-222017-08-29阿尔莫生物科技股份有限公司The method that disease and illness are treated using interleukin 10
RU2729161C2 (en)2014-10-232020-08-04ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК.Pharmaceutical compositions containing peptide versions, and methods of using them
TWI737583B (en)2014-11-062021-09-01藥華醫藥股份有限公司Dosage regimen for pegylated interferon
CA2968310A1 (en)2014-11-192016-05-26NZP UK Limited6.alpha.-alkyl-6,7-dione steroids as intermediates for the production of steroidal fxr modulators
TWI686401B (en)2014-11-192020-03-01英商Nzp英國有限公司Compounds
MX375864B (en)2014-11-192025-03-07Nzp Uk Ltd 5.BETA-6-ALKYL-7-HYDROXY-3-ONE STEROIDS AS INTERMEDIATE FOR THE PRODUCTION OF STEROID MODULATORS OF THE FARNESOID X RECEPTOR (FXR)
PL3221331T3 (en)2014-11-192020-03-31NZP UK Limited6-alkyl-7-hydroxy-4-en-3-one steroids as intermediates for the production of steroidal fxr modulators
MX385081B (en)2014-11-252025-03-14Bristol Myers Squibb Co METHODS AND COMPOSITIONS FOR 18F RADIO-LABELING OF BIOLOGICAL PRODUCTS.
CN107406494B (en)2014-11-252022-03-25百时美施贵宝公司 Novel PD-L1-binding peptides for imaging
CN107206099A (en)2015-01-202017-09-26约翰霍普金斯大学For sustained release antiglaucoma agent with the composition of control intraocular pressure
JP6846351B2 (en)2015-01-272021-03-24ザ・ジョンズ・ホプキンス・ユニバーシティー Hypotonic hydrogel formulation for enhanced transport of active agents on mucosal surfaces
US10618970B2 (en)2015-02-032020-04-14Armo Biosciences, Inc.Method of treating cancer with IL-10 and antibodies that induce ADCC
CA2976446A1 (en)2015-02-132016-08-18Sorrento Therapeutics, Inc.Antibody therapeutics that bind ctla4
JP7068825B2 (en)2015-04-082022-05-17ソレント・セラピューティクス・インコーポレイテッド Antibodies therapeutic agents that bind to CD38
CA2983276A1 (en)2015-04-242016-10-27Viiv Healthcare Uk (No 5) LimitedPolypeptides targeting hiv fusion
CA2981822C (en)2015-05-012023-04-11Allysta Pharmaceuticals, Inc.Adiponectin peptidomimetics for treating ocular disorders
JP7121496B2 (en)2015-05-282022-08-18アルモ・バイオサイエンシーズ・インコーポレイテッド Pegylated interleukin-10 for use in cancer therapy
EP3302528A1 (en)2015-05-292018-04-11Armo Biosciences, Inc.Methods of using interleukin-10 for treating diseases and disorders
EP3307296B1 (en)2015-06-152021-10-20The Board of Trustees of the Leland Stanford Junior UniversityTimp2 for use in treating aging-associated conditions
CN108025040A (en)2015-08-252018-05-11阿尔莫生物科技股份有限公司The method that disease and illness are treated using interleukin-10
ES2809125T3 (en)2015-09-232021-03-03Bristol Myers Squibb Co Glypican-3 binding fibronectin-based scaffold molecules
JP2018534269A (en)2015-10-012018-11-22エリージウム セラピューティクス, インコーポレイテッド Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en)2015-10-012019-07-02Elysium Therapeutics, Inc.Opioid compositions resistant to overdose and abuse
JP7407511B2 (en)2015-10-082024-01-04ネクター セラピューティクス Combination of IL-2Rβ selective agonist and long-acting IL-15 agonist
EP3888672A1 (en)2015-11-092021-10-06NGM Biopharmaceuticals, Inc.Methods for treatment of bile acid-related disorders
CN108463226B (en)2015-11-092022-04-15R.P.谢勒技术有限责任公司 Anti-CD22 antibody-maytansinoid conjugates and methods of using the same
EA201891388A1 (en)2015-12-112018-11-30Дайэкс Корп. PLASMA KALLIKREIN INHIBITORS AND THEIR APPLICATION FOR THE TREATMENT OF THE EXPOSURE OF HEREDITARY ANGIONEUROTIC DOMESTIC
CA3011455A1 (en)2016-01-272017-08-03Sutro Biopharma, Inc.Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
CN116333124A (en)2016-01-292023-06-27索伦托药业有限公司 Antigen-binding protein that binds to PD-L1
US10889625B2 (en)2016-02-232021-01-12The Regents Of The University Of Colorado, A Body CorporatePeptide-based methods for treating neurological injury
CN109153711B (en)2016-03-012022-04-26伊利诺伊大学理事会 L-asparaginase variants and fusion proteins with reduced L-glutaminase activity and enhanced stability
US20190022016A1 (en)2016-03-022019-01-24The Johns Hopkins UniversityCompositions for sustained release of anti-glaucoma agents to control intraocular pressure
WO2017160599A1 (en)2016-03-142017-09-21The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesUse of cd300b antagonists to treat sepsis and septic shock
AU2017250778B2 (en)2016-04-152021-09-23Beckman Coulter, Inc.Photoactive macromolecules and uses thereof
EP3458439B1 (en)2016-05-182021-12-08Alere San Diego, Inc.2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine analogs and methods for their synthesis and use
GB201608777D0 (en)2016-05-182016-06-29Dextra Lab LtdCompounds
GB201608776D0 (en)2016-05-182016-06-29Dextra Lab LtdMethods and compounds
WO2017210335A1 (en)2016-06-012017-12-07Bristol-Myers Squibb CompanyImaging methods using 18f-radiolabeled biologics
CN119120423A (en)2016-07-012024-12-13分解治疗有限责任公司 Optimized dinuclease fusions and methods
KR102820834B1 (en)2016-07-152025-06-13에프. 호프만-라 로슈 아게Method for purifying pegylated erythropoietin
US11628205B2 (en)2016-07-222023-04-18Nektar TherapeuticsConjugates of a factor VIII moiety having an oxime-containing linkage
US11248313B2 (en)2016-08-012022-02-15Trustees Of Tufts CollegeBiomimetic mechanical tension driven fabrication of nanofibrillar architecture
CN109562167A (en)2016-08-092019-04-02伊莱利利公司Combination therapy
JP7022746B2 (en)2016-10-242022-02-18ノヴォ ノルディスク アー/エス Bioassay for insulin preparations
US10350266B2 (en)2017-01-102019-07-16Nodus Therapeutics, Inc.Method of treating cancer with a multiple integrin binding Fc fusion protein
WO2018132516A1 (en)2017-01-102018-07-19Nodus TherapeuticsCombination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
EP3595663A4 (en)2017-03-172021-01-13Elysium Therapeutics, Inc.Polysubunit opioid prodrugs resistant to overdose and abuse
CN110461354A (en)2017-03-292019-11-15瑞华药业集团 protein conjugate
JP6935059B2 (en)2017-03-302021-09-15日油株式会社 A method for purifying polyethylene glycol having one carboxyl group
CA3060410A1 (en)2017-05-152018-11-22Nektar TherapeuticsLong-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods
AU2018283973B2 (en)2017-06-112025-04-24Molecular Express, Inc.Methods and compositions for substance use disorder vaccine formulations and uses thereof
US10174302B1 (en)2017-06-212019-01-08Xl-Protein GmbhModified L-asparaginase
WO2019023316A1 (en)2017-07-262019-01-31Sutro Biopharma, Inc.Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
CN111050784B (en)2017-08-112024-03-19伊利诺伊大学理事会 Truncated guinea pig L-asparaginase variants and methods of use
US11485781B2 (en)2017-08-172022-11-01Massachusetts Institute Of TechnologyMultiple specificity binders of CXC chemokines
KR102777015B1 (en)2017-08-222025-03-10사나바이오, 엘엘씨 Availability of interferon receptors and their uses
WO2019055931A1 (en)2017-09-182019-03-21Sutro Biopharma, Inc.Anti- folate receptor alpha antibody conjugates and their uses
WO2019063958A1 (en)2017-09-272019-04-04The University Of YorkBioconjugation of polypeptides
KR102020995B1 (en)2017-10-302019-09-16한국코러스 주식회사A method of preparing gcsf and polyol_conjugated conjugates with high yield
JP7544598B2 (en)2017-11-102024-09-03アーモ・バイオサイエンシーズ・インコーポレイテッド Compositions and methods of use of interleukin-10 in combination with immune checkpoint pathway inhibitors
MX2020005041A (en)2017-11-212020-10-12Univ Leland Stanford JuniorPartial agonists of interleukin-2.
WO2019133399A1 (en)2017-12-262019-07-04Becton, Dickinson And CompanyDeep ultraviolet-excitable water-solvated polymeric dyes
CN111741770A (en)2017-12-292020-10-02豪夫迈·罗氏有限公司 Methods for providing PEGylated protein compositions
PL3731872T3 (en)2017-12-292022-03-21F. Hoffmann-La Roche AgProcess for providing pegylated protein composition
SG11202005952TA (en)2017-12-292020-07-29Hoffmann La RocheProcess for providing pegylated protein composition
EP3775052B1 (en)2018-03-302024-06-05Becton, Dickinson and CompanyWater-soluble polymeric dyes having pendant chromophores
KR102167755B1 (en)2018-05-232020-10-19주식회사 큐어바이오Fragmented GRS polypeptide, mutants thereof and use thereof
CN112533629A (en)2018-06-192021-03-19阿尔莫生物科技股份有限公司Compositions and methods for combined use of IL-10 agents with chimeric antigen receptor cell therapy
EP3813867A1 (en)2018-07-222021-05-05Bioasis Technologies Inc.Treatment of lymmphatic metastases
EP3852811A1 (en)2018-09-172021-07-28Sutro Biopharma, Inc.Combination therapies with anti-folate receptor antibody conjugates
BR102018069598A2 (en)*2018-09-252020-04-07Fundação Oswaldo Cruz liposomal formulation, pharmaceutical composition, use of a liposomal formulation, method for treating cancer, and, process for preparing a liposomal formulation
CN110964116A (en)2018-09-262020-04-07北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc fusion protein and its conjugates
SG11202100935TA (en)2018-09-282021-02-25Massachusetts Inst TechnologyCollagen-localized immunomodulatory molecules and methods thereof
MX2021006259A (en)2018-11-302021-09-30Eirgen Pharma LtdOxyntomodulin peptide analog formulations.
CN113597319A (en)2019-01-042021-11-02分解治疗有限责任公司Treatment of xerosis with nuclease fusion proteins
US20220105150A1 (en)2019-01-182022-04-07The Regents Of The University Of Colorado, A Body CorporateAmphipathic alpha-helical antimicrobial peptides treat infections by gram-negative pathogens
US11235032B2 (en)2019-01-232022-02-01Massachusetts Institute Of TechnologyCombination immunotherapy dosing regimen for immune checkpoint blockade
WO2020160322A1 (en)2019-01-302020-08-06Horizon Pharma Rheumatology LlcTolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
WO2020227105A1 (en)2019-05-032020-11-12Sutro Biopharma, Inc.Anti-bcma antibody conjugates
US20220242871A1 (en)2019-06-102022-08-04Sutro Biopharma, Inc.5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF
WO2020257235A1 (en)2019-06-172020-12-24Sutro Biopharma, Inc.1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
CN112175088B (en)2019-07-022023-03-28江苏晟斯生物制药有限公司FIX fusion proteins, conjugates and uses thereof
JP2022545917A (en)2019-08-272022-11-01トニックス ファーマ リミテッド Modified TFF2 polypeptide
US20220409697A1 (en)2019-10-192022-12-29Ramea LlcExtended Half-life G-CSF and GM-CSF Vitamin D Conjugates
US20210221886A1 (en)2019-12-052021-07-22Sorrento Therapeutics, Inc.Compositions and Methods Comprising an Anti-CD47 Antibody in Combination with a Tumor Targeting Antibody
CA3164731A1 (en)2019-12-202021-06-24Regeneron Pharmaceuticals, Inc.Novel il2 agonists and methods of use thereof
CA3164456A1 (en)2019-12-272021-07-01Nof CorporationMethod for purifying polyethylene glycol compound
US20230183377A1 (en)2020-02-262023-06-15Sorrento Therapeutics, Inc.Activatable antigen binding proteins with universal masking moieties
US20240277878A1 (en)2020-02-282024-08-22Bristol-Myers Squibb CompanyRadiolabeled fibronectin based scaffolds and antibodies and theranostic uses thereof
EP4114852A1 (en)2020-03-032023-01-11Sutro Biopharma, Inc.Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2021195089A1 (en)2020-03-232021-09-30Sorrento Therapeutics, Inc.Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
CR20220530A (en)2020-04-222022-12-15Merck Sharp & Dohme LlcHUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAc DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER
JP2023524464A (en)2020-04-302023-06-12サイロパ ビー.ブイ. Anti-CD103 antibody
AU2021270563A1 (en)2020-05-122022-12-15Regeneron Pharmaceuticals, Inc.Novel IL10 agonists and methods of use thereof
US20210355468A1 (en)2020-05-182021-11-18Bioasis Technologies, Inc.Compositions and methods for treating lewy body dementia
US20210393787A1 (en)2020-06-172021-12-23Bioasis Technologies, Inc.Compositions and methods for treating frontotemporal dementia
EP4172207A1 (en)2020-06-262023-05-03Sorrento Therapeutics, Inc.Anti-pd1 antibodies and uses thereof
EP4171614A1 (en)2020-06-292023-05-03Resolve Therapeutics, LLCTreatment of sjogren's syndrome with nuclease fusion proteins
CA3128035A1 (en)2020-08-132022-02-13Bioasis Technologies, Inc.Combination therapies for delivery across the blood brain barrier
WO2022103983A2 (en)2020-11-112022-05-19Sutro Biopharma, Inc.Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
KR20240004659A (en)2021-04-302024-01-11셀진 코포레이션 Combination therapy using an anti-BCMA antibody-drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
JP2024534787A (en)2021-08-162024-09-26リジェネロン・ファーマシューティカルズ・インコーポレイテッド Novel IL27 receptor agonists and methods of use thereof
EP4155349A1 (en)2021-09-242023-03-29Becton, Dickinson and CompanyWater-soluble yellow green absorbing dyes
EP4430079A1 (en)2021-11-112024-09-18Regeneron Pharmaceuticals, Inc.Cd20-pd1 binding molecules and methods of use thereof
GB202117727D0 (en)2021-12-082022-01-19Univ EdinburghFap detection
EP4543494A1 (en)2022-06-272025-04-30Sutro Biopharma, Inc.Beta-glucuronide linker-payloads, protein conjugates thereof, and methods thereof
JP2025525445A (en)2022-06-302025-08-05ストロ バイオファーマ インコーポレーテッド Anti-ROR1 antibodies and antibody conjugates, compositions comprising anti-ROR1 antibodies or antibody conjugates, and methods of making and using anti-ROR1 antibodies and antibody conjugates
AU2023298234A1 (en)2022-07-012025-01-16Beckman Coulter, Inc.Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
EP4554947A1 (en)2022-07-152025-05-21Sutro Biopharma, Inc.Protease/enzyme cleavable linker-payloads and protein conjugates
WO2024044327A1 (en)2022-08-262024-02-29Beckman Coulter, Inc.Dhnt monomers and polymer dyes with modified photophysical properties
WO2024044780A1 (en)2022-08-262024-02-29Sutro Biopharma, Inc.Interleukin-18 variants and uses thereof
IL319526A (en)2022-09-302025-05-01Extend Biosciences IncLong-acting parathyroid hormone
WO2024098023A2 (en)2022-11-042024-05-10Sutro Biopharma, Inc.Interferon alpha polypeptides and conjugates
CN116178733B (en)*2023-03-032023-08-01浙江博美生物技术有限公司Branched monodisperse PEG derivative based on trifunctional amino acid, preparation method and application
WO2024196805A1 (en)2023-03-172024-09-26Beckman Coulter, Inc.Benzothienopyrrole cyanine dyes
US20240400687A1 (en)2023-05-102024-12-05Regeneron Pharmaceuticals, Inc.Cd20-pd1 binding molecules and methods of use thereof
WO2025006676A2 (en)2023-06-272025-01-02Firecyte Therapeutics, Inc.Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof
US20250108048A1 (en)2023-07-312025-04-03Sutro Biopharma, Inc.Sting agonist compounds and conjugates
US12269875B2 (en)2023-08-032025-04-08Jeff R. PetersonGout flare prevention methods using IL-1BETA blockers
WO2025064842A1 (en)2023-09-212025-03-27Beckman Coulter, Inc.Dihydrophenanthrene (dhp) bridged dyes for use in flow cytometry
WO2025081117A2 (en)2023-10-132025-04-17Sutro Biopharma, Inc.Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2025080711A1 (en)2023-10-132025-04-17Sutro Biopharma, Inc.Dual payload antibody drug conjugates
WO2025147696A1 (en)2024-01-052025-07-10Resolve Therapeutics, LlcTreatment of symptoms associated with sars-cov viral infection or a prior sars-cov viral infection with nuclease agents

Citations (17)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US40076A (en)*1863-09-22Improvement in molds for
US52430A (en)*1866-02-06Improved heel-cutter
US52443A (en)*1866-02-06Improved brad-awl handle
US4179337A (en)*1973-07-201979-12-18Davis Frank FNon-immunogenic polypeptides
US4650909A (en)*1984-11-281987-03-17Yoakum George HPolyethylene glycol (PEG) reagent
US4722906A (en)*1982-09-291988-02-02Bio-Metric Systems, Inc.Binding reagents and methods
US5122614A (en)*1989-04-191992-06-16Enzon, Inc.Active carbonates of polyalkylene oxides for modification of polypeptides
US5168057A (en)*1987-09-301992-12-01Beckman Instruments, Inc.Trifunctional conjugates
US5183660A (en)*1990-08-281993-02-02Sumitomo Pharmaceuticals Company, LimitedPolyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides
US5324844A (en)*1989-04-191994-06-28Enzon, Inc.Active carbonates of polyalkylene oxides for modification of polypeptides
US5359030A (en)*1993-05-101994-10-25Protein Delivery, Inc.Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5605976A (en)*1995-05-151997-02-25Enzon, Inc.Method of preparing polyalkylene oxide carboxylic acids
US5643575A (en)*1993-10-271997-07-01Enzon, Inc.Non-antigenic branched polymer conjugates
US5756593A (en)*1995-05-151998-05-26Enzon, Inc.Method of preparing polyalkyene oxide carboxylic acids
US5919455A (en)*1993-10-271999-07-06Enzon, Inc.Non-antigenic branched polymer conjugates
US5935564A (en)*1996-03-061999-08-10Amgen Inc.Use of hydrophobic interaction chromatography to purify polyethylene glycols
US6362254B2 (en)*1998-03-122002-03-26Shearwater CorporationPoly(ethylene glycol) derivatives with proximal reactive groups

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JP2997004B2 (en)*1989-05-262000-01-11住友製薬株式会社 Polyethylene glycol derivative, modified peptide and method for producing the same
EP0400472B1 (en)*1989-05-271996-04-03Sumitomo Pharmaceuticals Company, LimitedProcess for preparing polyethylene glycol derivatives and modified protein.
EP0632082B1 (en)*1993-06-291997-04-02"HEYLECINA", Société AnonymePreparation of activated carbamates of poly(alkylene glycol) and their use
US5932462A (en)*1995-01-101999-08-03Shearwater Polymers, Inc.Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SI1075281T1 (en)*1998-04-282005-02-28Applied Research Systems Ars Holding N.V.Polyol-ifn-beta conjugates

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US40076A (en)*1863-09-22Improvement in molds for
US52430A (en)*1866-02-06Improved heel-cutter
US52443A (en)*1866-02-06Improved brad-awl handle
US4179337A (en)*1973-07-201979-12-18Davis Frank FNon-immunogenic polypeptides
US4722906A (en)*1982-09-291988-02-02Bio-Metric Systems, Inc.Binding reagents and methods
US4650909A (en)*1984-11-281987-03-17Yoakum George HPolyethylene glycol (PEG) reagent
US5168057A (en)*1987-09-301992-12-01Beckman Instruments, Inc.Trifunctional conjugates
US5122614A (en)*1989-04-191992-06-16Enzon, Inc.Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en)*1989-04-191994-06-28Enzon, Inc.Active carbonates of polyalkylene oxides for modification of polypeptides
US5183660A (en)*1990-08-281993-02-02Sumitomo Pharmaceuticals Company, LimitedPolyethylene glycol derivatives, their modified peptides, methods for producing them and use of the modified peptides
US5359030A (en)*1993-05-101994-10-25Protein Delivery, Inc.Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5438040A (en)*1993-05-101995-08-01Protein Delivery, Inc.Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en)*1993-10-271997-07-01Enzon, Inc.Non-antigenic branched polymer conjugates
US5919455A (en)*1993-10-271999-07-06Enzon, Inc.Non-antigenic branched polymer conjugates
US6113906A (en)*1993-10-272000-09-05Enzon, Inc.Water-soluble non-antigenic polymer linkable to biologically active material
US5605976A (en)*1995-05-151997-02-25Enzon, Inc.Method of preparing polyalkylene oxide carboxylic acids
US5681567A (en)*1995-05-151997-10-28Enzon, Inc.Method of preparing polyalkylene oxide carboxylic acids
US5756593A (en)*1995-05-151998-05-26Enzon, Inc.Method of preparing polyalkyene oxide carboxylic acids
US5935564A (en)*1996-03-061999-08-10Amgen Inc.Use of hydrophobic interaction chromatography to purify polyethylene glycols
US6362254B2 (en)*1998-03-122002-03-26Shearwater CorporationPoly(ethylene glycol) derivatives with proximal reactive groups
US6437025B1 (en)*1998-03-122002-08-20Shearwater CorporationPoly(ethylene glycol) derivatives with proximal reactive groups

Cited By (251)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US7419600B2 (en)1995-01-102008-09-02Nektar Therapeutics Al, CorporationMethod for purifying a branched water-soluble polymer
US8546493B2 (en)1995-01-102013-10-01Nektar TherapeuticsMulti-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US20050090650A1 (en)*1995-01-102005-04-28Harris J. M.Purified polymers for modification of surfaces and molecules
US8354477B2 (en)1995-01-102013-01-15Nektar TherapeuticsMulti-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US20100298496A1 (en)*1995-01-102010-11-25Nektar TherapeuticsMulti-armed, monofunctional, and hydrolytically stable derivatives of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US7786221B2 (en)1995-01-102010-08-31Nektar TherapeuticsMulti-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules
US8450470B2 (en)2003-03-052013-05-28Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090181032A1 (en)*2003-03-052009-07-16Bookbinder Louis HSoluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20040268425A1 (en)*2003-03-052004-12-30Deliatroph Pharmaceuticals, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US11723959B2 (en)2003-03-052023-08-15Halozyme, Inc.Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide
US20090214505A1 (en)*2003-03-052009-08-27Bookbinder Louis HSoluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090181013A1 (en)*2003-03-052009-07-16Bookbinder Louis HSoluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US9677061B2 (en)2003-03-052017-06-13Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US7871607B2 (en)2003-03-052011-01-18Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20090253175A1 (en)*2003-03-052009-10-08Bookbinder Louis HSoluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8431124B2 (en)2003-03-052013-04-30Halozyme, Inc.Methods for treating a disease characterized by an excess of hyaluronan by administering a soluble hyaluronidase glycoprotein (sHASEGP)
US10898551B2 (en)2003-03-052021-01-26Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20090123367A1 (en)*2003-03-052009-05-14DelfmemsSoluble Glycosaminoglycanases and Methods of Preparing and Using Soluble Glycosaminoglycanases
US7767429B2 (en)2003-03-052010-08-03Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20050260186A1 (en)*2003-03-052005-11-24Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en)*2003-03-052006-05-18Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US8202517B2 (en)2003-03-052012-06-19Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US10286044B2 (en)2003-03-052019-05-14Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US8431380B2 (en)2003-03-052013-04-30Halozyme, Inc.Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20110152359A1 (en)*2003-03-052011-06-23Bookbinder Louis HSoluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising threreof
US7887789B2 (en)2003-05-232011-02-15Nektar TherapeuticsPolymer derivatives having particular atom arrangements
US20050009988A1 (en)*2003-05-232005-01-13Harris J. MiltonPolymer derivatives having particular atom arrangements
US20110178242A1 (en)*2003-05-232011-07-21Nektar TherapeuticsMethods for Forming Polymer-Drug Conjugates
US20060275252A1 (en)*2003-05-232006-12-07Harris J MConjugates formed from polymer derivatives having particular atom arrangements
US8633277B2 (en)2003-05-232014-01-21Nektar TherapeuticsMethods for forming polymer-drug conjugates
US10646578B2 (en)2003-05-232020-05-12Nektar TherapeuticsPolymer derivatives having particular atom arrangements
US7947261B2 (en)2003-05-232011-05-24Nektar TherapeuticsConjugates formed from polymer derivatives having particular atom arrangements
US9913913B2 (en)2003-05-232018-03-13Nektar TherapeuticsMethod for preparing a polymeric reagent
US11446385B2 (en)2003-05-232022-09-20Nektar TherapeuticsPolymer derivatives having particular atom arrangements
US9044516B2 (en)2003-05-232015-06-02Nektar TherapeuticsPharmaceutical compositions of conjugates formed from polymer derivatives having particular atom arrangements
US9399070B2 (en)2003-05-232016-07-26Nektar TherapeuticsCompositions comprising a polymeric reagent and a pharmacologically active agent
US20080300163A1 (en)*2004-02-022008-12-04Ambrx, Inc.Modified Human Four Helical Bundle Polypeptides And Their Uses
US8232371B2 (en)2004-02-022012-07-31Ambrx, Inc.Modified human interferon polypeptides and their uses
US20050170404A1 (en)*2004-02-022005-08-04Ambrx, Inc.Modified human growth hormone polypeptides and their uses
US20080207877A1 (en)*2004-02-022008-08-28Ambrx, Inc.Modified Human Four Helical Bundle Polypeptides and Their Uses
US8119603B2 (en)2004-02-022012-02-21Ambrx, Inc.Modified human interferon polypeptides and their uses
US8097702B2 (en)2004-02-022012-01-17Ambrx, Inc.Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses
US20080114155A1 (en)*2004-02-022008-05-15Ambrx, Inc.Modified Human Interferon Polypeptides and Their Uses
US20080146781A1 (en)*2004-02-022008-06-19Ambrx, Inc.Modified Human Four Helical Bundle Polypeptides and Their Uses
US20080108791A1 (en)*2004-02-022008-05-08Ambrx, Inc.Modified Human Interferon Polypeptides and Their Uses
US20080103293A1 (en)*2004-02-022008-05-01Ambrx, Inc.Modified Human Growth Hormone Polypeptides and Their Uses
US20080097083A1 (en)*2004-02-022008-04-24Ambrx, Inc.Modified Human Four Helical Bundle Polypeptides and Their Uses
EP2327724A2 (en)2004-02-022011-06-01Ambrx, Inc.Modified human growth hormone polypeptides and their uses
US8778880B2 (en)2004-02-022014-07-15Ambrx, Inc.Human growth hormone modified at position 35
US8906676B2 (en)2004-02-022014-12-09Ambrx, Inc.Modified human four helical bundle polypeptides and their uses
US8907064B2 (en)2004-02-022014-12-09Ambrx, Inc.Modified human four helical bundle polypeptides and their uses
US9260472B2 (en)2004-02-022016-02-16Ambrx, Inc.Modified human four helical bundle polypeptides and their uses
US7632924B2 (en)2004-06-182009-12-15Ambrx, Inc.Antigen-binding polypeptides and their uses
US20080085277A1 (en)*2004-06-182008-04-10Ambrx, Inc.Novel antigen-binding polypeptides and their uses
US20080081038A1 (en)*2004-06-182008-04-03Ambrx, Inc.Novel antigen-binding polypeptides and their uses
WO2006009901A2 (en)2004-06-182006-01-26Ambrx, Inc.Novel antigen-binding polypeptides and their uses
US20080050374A1 (en)*2004-06-182008-02-28Ambrx, Inc.Novel antigen-binding polypeptides and their uses
US20060153860A1 (en)*2004-06-182006-07-13Ambrx, Inc.Novel antigen-binding polypeptides and their uses
US9175083B2 (en)2004-06-182015-11-03Ambrx, Inc.Antigen-binding polypeptides and their uses
WO2006019950A3 (en)*2004-07-162006-08-03Nektar Therapeutics Al CorpConjugates of a gm-csf moiety and a polymer
US20060019347A1 (en)*2004-07-212006-01-26Ambrx, Inc.Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7638299B2 (en)2004-07-212009-12-29Ambrx, Inc.Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US20100048871A1 (en)*2004-07-212010-02-25Ambrx, Inc.Biosynthetic Polypeptides Utilizing Non-Naturally Encoded Amino Acids
US8080391B2 (en)2004-12-222011-12-20Ambrx, Inc.Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
US7846689B2 (en)2004-12-222010-12-07Ambrx, Inc.Compositions of aminoacyl-tRNA synthetase and uses thereof
US7947473B2 (en)2004-12-222011-05-24Ambrx, Inc.Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid
US20080199909A1 (en)*2004-12-222008-08-21Ambrx, Inc.Methods for Expression and Purification of Recombinant Human Growth Hormone
US20100174054A1 (en)*2004-12-222010-07-08Ambrx, Inc.Compositions of Aminoacyl-tRNA Synthetase and Uses Thereof
US20060135427A1 (en)*2004-12-222006-06-22Ambrx, Inc.Formulations of human growth hormone comprising a non-naturally encoded amino acid
US7736872B2 (en)2004-12-222010-06-15Ambrx, Inc.Compositions of aminoacyl-TRNA synthetase and uses thereof
US7816320B2 (en)2004-12-222010-10-19Ambrx, Inc.Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35
US20080107680A1 (en)*2004-12-222008-05-08Ambrx, Inc.Modified Human Growth Hormone
US8178108B2 (en)2004-12-222012-05-15Ambrx, Inc.Methods for expression and purification of recombinant human growth hormone
US7858344B2 (en)2004-12-222010-12-28Ambrx, Inc.Compositions of aminoacyl-tRNA synthetase and uses thereof
US7838265B2 (en)2004-12-222010-11-23Ambrx, Inc.Compositions of aminoacyl-tRNA synthetase and uses thereof
EP2284191A2 (en)2004-12-222011-02-16Ambrx, Inc.Process for the preparation of hGH
US7959926B2 (en)2004-12-222011-06-14Ambrx, Inc.Methods for expression and purification of recombinant human growth hormone mutants
US7829310B2 (en)2004-12-222010-11-09Ambrx, Inc.Compositions of aminoacyl-tRNA synthetase and uses thereof
US7939496B2 (en)2004-12-222011-05-10Ambrx, Inc.Modified human growth horomone polypeptides and their uses
US7883866B2 (en)2004-12-222011-02-08Ambrx, Inc.Compositions of aminoacyl-tRNA synthetase and uses thereof
US8143216B2 (en)2004-12-222012-03-27Ambrx, Inc.Modified human growth hormone
US8163695B2 (en)2004-12-222012-04-24AmbrxFormulations of human growth hormone comprising a non-naturally encoded amino acid
US8178494B2 (en)2004-12-222012-05-15Ambrx, Inc.Modified human growth hormone formulations with an increased serum half-life
WO2006091871A1 (en)2005-02-232006-08-31Halozyme Therapeutics, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP3943501A1 (en)2005-02-232022-01-26Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7829081B2 (en)2005-02-232010-11-09Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US10588983B2 (en)2005-02-232020-03-17Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US7846431B2 (en)2005-02-232010-12-07Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
EP3045472A1 (en)2005-02-232016-07-20Halozyme, Inc.Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20100196423A1 (en)*2005-02-232010-08-05Bookbinder Louis HSoluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US8093356B2 (en)2005-06-032012-01-10Ambrx, Inc.Pegylated human interferon polypeptides
US7632823B2 (en)2005-08-182009-12-15Ambrx, Inc.Compositions of tRNA and uses thereof
US20080153745A1 (en)*2005-08-182008-06-26Ambrx, In.Compositions of tRNA and uses thereof
US9488660B2 (en)2005-11-162016-11-08Ambrx, Inc.Methods and compositions comprising non-natural amino acids
US20080317670A1 (en)*2005-12-142008-12-25Ambrx, Inc.Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides
US8053560B2 (en)2006-09-082011-11-08Ambrx, Inc.Modified human plasma polypeptide or Fc scaffolds and their uses
US8420792B2 (en)2006-09-082013-04-16Ambrx, Inc.Suppressor tRNA transcription in vertebrate cells
WO2008030558A2 (en)2006-09-082008-03-13Ambrx, Inc.Modified human plasma polypeptide or fc scaffolds and their uses
US20080113411A1 (en)*2006-09-082008-05-15Ambrx, Inc.Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses
US20080113412A1 (en)*2006-09-082008-05-15Ambrx, Inc.Modified Human Plasma Polypeptide or Fc Scaffolds and Their Uses
US9133495B2 (en)2006-09-082015-09-15Ambrx, Inc.Hybrid suppressor tRNA for vertebrate cells
US7919591B2 (en)2006-09-082011-04-05Ambrx, Inc.Modified human plasma polypeptide or Fc scaffolds and their uses
US8022186B2 (en)2006-09-082011-09-20Ambrx, Inc.Modified human plasma polypeptide or Fc scaffolds and their uses
US8618257B2 (en)2006-09-082013-12-31Ambrx, Inc.Modified human plasma polypeptide or Fc scaffolds and their uses
US9975936B2 (en)2007-03-302018-05-22Ambrx, Inc.Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US9517273B2 (en)2007-03-302016-12-13Ambrx, Inc.Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US11993637B2 (en)2007-03-302024-05-28Ambrx, Inc.Modified FGF-21 polypeptides with non-naturally encoded amino acids
US10377805B2 (en)2007-03-302019-08-13Ambrx, Inc.Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
US9079971B2 (en)2007-03-302015-07-14Ambrx, Inc.Modified FGF-21 polypeptides comprising non-naturally occurring amino acids
US8383365B2 (en)2007-03-302013-02-26Ambrx, Inc.Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives
US8012931B2 (en)2007-03-302011-09-06Ambrx, Inc.Modified FGF-21 polypeptides and their uses
US10961291B2 (en)2007-03-302021-03-30Ambrx, Inc.Modified FGF-21 polypeptides and their uses
US8114630B2 (en)2007-05-022012-02-14Ambrx, Inc.Modified interferon beta polypeptides and their uses
WO2009067636A2 (en)2007-11-202009-05-28Ambrx, Inc.Modified insulin polypeptides and their uses
US8946148B2 (en)2007-11-202015-02-03Ambrx, Inc.Modified insulin polypeptides and their uses
EP2930182A1 (en)2007-11-202015-10-14Ambrx, Inc.Modified insulin polypeptides and their uses
EP3103880A1 (en)2008-02-082016-12-14Ambrx, Inc.Modified leptin polypeptides and their uses
US9938333B2 (en)2008-02-082018-04-10Ambrx, Inc.Modified leptin polypeptides and their uses
US9775889B2 (en)2008-03-062017-10-03Halozyme, Inc.Methods of treatment of cellulite
US9833498B2 (en)2008-03-062017-12-05Halozyme, Inc.Methods of treatment of collagen-mediated diseases and conditions
EP3192525A1 (en)2008-04-142017-07-19Halozyme, Inc.Modified hyaluronidases for use in treating hyaluronan-associated diseases and conditions
US10328130B2 (en)2008-04-142019-06-25Halozyme, Inc.Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
EP2662090A1 (en)2008-04-142013-11-13Halozyme, Inc.Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
US8318154B2 (en)2008-04-282012-11-27Halozyme, Inc.Super fast-acting insulin compositions
EP2705850A2 (en)2008-04-282014-03-12Halozyme, Inc.Super fast-acting insulin compositions
WO2010011735A2 (en)2008-07-232010-01-28Ambrx, Inc.Modified bovine g-csf polypeptides and their uses
EP3225248A1 (en)2008-07-232017-10-04Ambrx, Inc.Modified bovine g-csf polypeptides and their uses
US10138283B2 (en)2008-07-232018-11-27Ambrx, Inc.Modified bovine G-CSF polypeptides and their uses
US9121024B2 (en)2008-09-262015-09-01Ambrx, Inc.Non-natural amino acid replication-dependent microorganisms and vaccines
US8278418B2 (en)2008-09-262012-10-02Ambrx, Inc.Modified animal erythropoietin polypeptides and their uses
EP3216800A1 (en)2008-09-262017-09-13Ambrx, Inc.Modified animal erythropoietin polypeptides and their uses
US9121025B2 (en)2008-09-262015-09-01Ambrx, Inc.Non-natural amino acid replication-dependent microorganisms and vaccines
US8569233B2 (en)2008-09-262013-10-29Eli Lilly And CompanyModified animal erythropoietin polypeptides and their uses
US9156899B2 (en)2008-09-262015-10-13Eli Lilly And CompanyModified animal erythropoietin polypeptides and their uses
US9644014B2 (en)2008-09-262017-05-09Ambrx, Inc.Modified animal erythropoietin polypeptides and their uses
US10428333B2 (en)2008-09-262019-10-01Ambrx Inc.Non-natural amino acid replication-dependent microorganisms and vaccines
US9284543B2 (en)2008-12-092016-03-15Halozyme, Inc.Neutral active soluble truncated PH20 polypeptides and uses thereof
EP3037529A1 (en)2008-12-092016-06-29Halozyme, Inc.Extended soluble ph20 polypeptides and uses thereof
US8927249B2 (en)2008-12-092015-01-06Halozyme, Inc.Extended soluble PH20 polypeptides and uses thereof
WO2010077297A1 (en)2008-12-092010-07-08Halozyme, Inc.Extended soluble ph20 polypeptides and uses thereof
US11046946B2 (en)2009-07-062021-06-29Jazz Pharmaceuticals Ii SasPEGylated L-asparaginase
WO2011003886A1 (en)2009-07-062011-01-13Alize Pharma IiPegylated l-asparaginase
USRE49736E1 (en)2009-07-062023-11-28Jazz Pharmaceuticals Ii SasPegylated L-asparaginase
US9084743B2 (en)2009-09-172015-07-21Baxter International Inc.Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
WO2011034604A2 (en)2009-09-172011-03-24Baxter Healthcare, S.A.Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
EP2805964A1 (en)2009-12-212014-11-26Ambrx, Inc.Modified bovine somatotropin polypeptides and their uses
EP2805965A1 (en)2009-12-212014-11-26Ambrx, Inc.Modified porcine somatotropin polypeptides and their uses
US9878046B2 (en)2010-07-202018-01-30Halozyme, Inc.Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
US10265410B2 (en)2010-07-202019-04-23Halozyme, Inc.Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
WO2012012300A2 (en)2010-07-202012-01-26Halozyme, Inc.Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects
US11786578B2 (en)2010-08-172023-10-17Ambrx, Inc.Modified relaxin polypeptides and their uses
US11311605B2 (en)2010-08-172022-04-26Ambrx, Inc.Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
EP4302783A2 (en)2010-08-172024-01-10Ambrx, Inc.Modified relaxin polypeptides and their uses
US10751391B2 (en)2010-08-172020-08-25Ambrx, Inc.Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
US10702588B2 (en)2010-08-172020-07-07Ambrx, Inc.Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
US9567386B2 (en)2010-08-172017-02-14Ambrx, Inc.Therapeutic uses of modified relaxin polypeptides
US9452222B2 (en)2010-08-172016-09-27Ambrx, Inc.Nucleic acids encoding modified relaxin polypeptides
US9962450B2 (en)2010-08-172018-05-08Ambrx, Inc.Method of treating heart failure with modified relaxin polypeptides
US8735539B2 (en)2010-08-172014-05-27Ambrx, Inc.Relaxin polypeptides comprising non-naturally encoded amino acids
US10253083B2 (en)2010-08-172019-04-09Ambrx, Inc.Therapeutic uses of modified relaxin polypeptides
US11439710B2 (en)2010-08-172022-09-13Ambrx, Inc.Nucleic acids encoding modified relaxin polypeptides
WO2012024452A2 (en)2010-08-172012-02-23Ambrx, Inc.Modified relaxin polypeptides and their uses
US12138296B2 (en)2010-09-232024-11-12Elanco Us Inc.Formulations for bovine granulocyte colony stimulating factor and variants thereof
US11273202B2 (en)2010-09-232022-03-15Elanco Us Inc.Formulations for bovine granulocyte colony stimulating factor and variants thereof
US9333244B2 (en)2011-02-082016-05-10Halozyme, Inc.Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
EP2907504A1 (en)2011-02-082015-08-19Halozyme, Inc.Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2012109387A1 (en)2011-02-082012-08-16Halozyme, Inc.Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
WO2012174480A2 (en)2011-06-172012-12-20Halozyme, Inc.Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US9993529B2 (en)2011-06-172018-06-12Halozyme, Inc.Stable formulations of a hyaluronan-degrading enzyme
WO2013040501A1 (en)2011-09-162013-03-21Pharmathene, Inc.Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and uses thereof
US9458442B2 (en)2011-10-242016-10-04Halozyme, Inc.Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
EP2915542A1 (en)2011-10-242015-09-09Halozyme, Inc.Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
US8846034B2 (en)2011-10-242014-09-30Halozyme, Inc.Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
WO2013063155A2 (en)2011-10-242013-05-02Halozyme, Inc.Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
US12264345B1 (en)2011-12-302025-04-01Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12152262B2 (en)2011-12-302024-11-26Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12077791B2 (en)2011-12-302024-09-03Halozyme, Inc.PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof
US12054758B2 (en)2011-12-302024-08-06Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US11952600B2 (en)2011-12-302024-04-09Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12091692B2 (en)2011-12-302024-09-17Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12060590B2 (en)2011-12-302024-08-13Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12104184B2 (en)2011-12-302024-10-01Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12049652B2 (en)2011-12-302024-07-30Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12123035B2 (en)2011-12-302024-10-22Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12104185B2 (en)2011-12-302024-10-01Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12018298B2 (en)2011-12-302024-06-25Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12037618B2 (en)2011-12-302024-07-16Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US9447401B2 (en)2011-12-302016-09-20Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12195773B2 (en)2011-12-302025-01-14Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
EP3130347A1 (en)2011-12-302017-02-15Halozyme, Inc.Ph20 polypeptide variants, formulations and uses thereof
US11066656B2 (en)2011-12-302021-07-20Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12110520B2 (en)2011-12-302024-10-08Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US11041149B2 (en)2011-12-302021-06-22Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US10865400B2 (en)2011-12-302020-12-15Halozyme, Inc.PH20 polypeptide variants, formulations and uses thereof
US12371685B2 (en)2011-12-302025-07-29Halozyme, Inc.PH20 polypeptide variants with a modification at position 324 of the PH20 polypeptide and a method of making thereof
WO2013151774A1 (en)2012-04-042013-10-10Halozyme, Inc.Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
US9913822B2 (en)2012-04-042018-03-13Halozyme, Inc.Combination therapy with an anti-hyaluronan agent and therapeutic agent
US10137104B2 (en)2012-04-042018-11-27Halozyme, Inc.Combination therapy with an anti-hyaluronan agent and therapeutic agent
EP3505534A1 (en)2012-06-082019-07-03Sutro Biopharma, Inc.Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
WO2013185115A1 (en)2012-06-082013-12-12Sutro Biopharma, Inc.Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (en)2012-06-262017-03-01Sutro Biopharma, Inc.Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
EP3584255A1 (en)2012-08-312019-12-25Sutro Biopharma, Inc.Modified amino acids comprising an azido group
WO2014036492A1 (en)2012-08-312014-03-06Sutro Biopharma, Inc.Modified amino acids comprising an azido group
EP4074728A1 (en)2012-08-312022-10-19Sutro Biopharma, Inc.Modified peptides comprising an azido group
WO2014062856A1 (en)2012-10-162014-04-24Halozyme, Inc.Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US9278124B2 (en)2012-10-162016-03-08Halozyme, Inc.Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
WO2015003167A1 (en)2013-07-032015-01-08Halozyme, Inc.Thermally stable ph20 hyaluronidase variants and uses thereof
EP3336103A1 (en)2013-07-102018-06-20Sutro Biopharma, Inc.Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015006555A2 (en)2013-07-102015-01-15Sutro Biopharma, Inc.Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015054658A1 (en)2013-10-112015-04-16Sutro Biopharma, Inc.Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US11414489B2 (en)2014-08-282022-08-16Halozyme, Inc.Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
WO2016033555A1 (en)2014-08-282016-03-03Halozyme, Inc.Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
US9969998B2 (en)2014-10-142018-05-15Halozyme, Inc.Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
WO2016061286A2 (en)2014-10-142016-04-21Halozyme, Inc.Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US11584923B2 (en)2014-10-142023-02-21Halozyme, Inc.Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
US10377806B2 (en)2014-10-242019-08-13Bristol-Myers Squibb CompanyMethods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof
US9631004B2 (en)2014-10-242017-04-25Bristol-Myers Squibb CompanyModified FGF-21 polypeptides comprising an internal deletion and uses thereof
US12247058B2 (en)2014-10-242025-03-11Bristol-Myers Squibb CompanyNucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof
US11248031B2 (en)2014-10-242022-02-15Bristol-Myers Squibb CompanyMethods of treating diseases associated with fibrosis using modified FGF-21 polypeptides
US9434778B2 (en)2014-10-242016-09-06Bristol-Myers Squibb CompanyModified FGF-21 polypeptides comprising an internal deletion and uses thereof
US10189883B2 (en)2014-10-242019-01-29Bristol-Myers Squibb CompanyTherapeutic uses of modified FGF-21 polypeptides
WO2017094897A1 (en)2015-12-042017-06-08全薬工業株式会社Anti-il-17 aptamer having improved retention in blood
US11013756B2 (en)2015-12-042021-05-25Zenyaku Kogyo Co., Ltd.Anti-IL-17 aptamer having improved retention in blood
WO2018085493A1 (en)2016-11-042018-05-11Georgia State University Research Foundation, Inc.Endotoxin free asparaginase
US12097242B2 (en)2017-02-082024-09-24Bristol-Myers Squibb CompanyTreatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides
US11364281B2 (en)2017-02-082022-06-21Bristol-Myers Squibb CompanyModified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof
US11185570B2 (en)2017-02-082021-11-30Bristol-Myers Squibb CompanyMethod of treating cardiovascular disease and heart failure with modified relaxin polypeptides
US10266578B2 (en)2017-02-082019-04-23Bristol-Myers Squibb CompanyModified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US12097241B2 (en)2017-02-082024-09-24Bristol-Myers Squibb CompanyMethods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides
US11807882B2 (en)2017-06-222023-11-07Vertex Pharmaceuticals IncorporatedModified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
US12173337B2 (en)2017-06-222024-12-24Vertex Pharmaceuticals, IncorporatedNucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
WO2018237201A1 (en)2017-06-222018-12-27Catalyst Biosciences, Inc. MODIFIED MEMBRANE-LIKE SERINE PROTEASE-1 POLYPEPTIDES (MTSP-1) AND METHODS OF USE
US10781435B2 (en)2017-06-222020-09-22Catalyst Biosciences, Inc.Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
US10954501B2 (en)2017-06-222021-03-23Catalyst Biosciences, Inc.Nucleic acid encoding modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
US11401513B2 (en)2017-06-222022-08-02Catalyst Biosciences, Inc.Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
WO2019222435A1 (en)2018-05-162019-11-21Halozyme, Inc.Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
WO2020056066A1 (en)2018-09-112020-03-19Ambrx, Inc.Interleukin-2 polypeptide conjugates and their uses
US12049485B2 (en)2018-09-112024-07-30Ambrx, Inc.Interleukin-2 polypeptide conjugates and their uses
EP4389145A2 (en)2018-09-112024-06-26Ambrx, Inc.Interleukin-2 polypeptide conjugates and their uses
WO2020082057A1 (en)2018-10-192020-04-23Ambrx, Inc.Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020140101A1 (en)2018-12-282020-07-02Catalyst Biosciences, Inc.Modified urokinase-type plasminogen activator polypeptides and methods of use
US12331334B2 (en)2018-12-282025-06-17Vertex Pharmaceuticals, IncorporatedModified urokinase-type plasminogen activator polypeptides and methods of use
US11613744B2 (en)2018-12-282023-03-28Vertex Pharmaceuticals IncorporatedModified urokinase-type plasminogen activator polypeptides and methods of use
WO2020168017A1 (en)2019-02-122020-08-20Ambrx, Inc.Compositions containing, methods and uses of antibody-tlr agonist conjugates
WO2021183832A1 (en)2020-03-112021-09-16Ambrx, Inc.Interleukin-2 polypeptide conjugates and methods of use thereof
WO2022040596A1 (en)2020-08-202022-02-24Ambrx, Inc.Antibody-tlr agonist conjugates, methods and uses thereof
WO2022212571A1 (en)2021-03-302022-10-06Jazz Pharmaceuticals Ireland Ltd.Dosing and administration of recombinant l-asparaginase
WO2022211829A1 (en)2021-03-302022-10-06Jazz Pharmaceuticals Ireland Ltd.Dosing of recombinant l-asparaginase
WO2022212899A1 (en)2021-04-032022-10-06Ambrx, Inc.Anti-her2 antibody-drug conjugates and uses thereof
US12441992B2 (en)2021-06-032025-10-14Jazz Pharmaceuticals Ii SasMethod of treating AML with PEGylated l-asparaginase
WO2024015529A2 (en)2022-07-142024-01-18Jazz Pharmaceuticals Ireland Ltd.Combination therapies involving l-asparaginase

Also Published As

Publication numberPublication date
US20100298496A1 (en)2010-11-25
AU4755596A (en)1996-07-31
US7786221B2 (en)2010-08-31
US8354477B2 (en)2013-01-15
US8546493B2 (en)2013-10-01
WO1996021469A1 (en)1996-07-18
US20010007765A1 (en)2001-07-12
US20050090650A1 (en)2005-04-28
US20090054590A1 (en)2009-02-26
US20130177961A1 (en)2013-07-11
US5932462A (en)1999-08-03
US7419600B2 (en)2008-09-02

Similar Documents

PublicationPublication DateTitle
US7786221B2 (en)Multi-armed, monofunctional, and hydrolytically stable derivatives of poly (ethylene glycol) and related polymers for modification of surfaces and molecules
US10456476B2 (en)Method involving 1-benzotriazolyl carbonate esters of poly(ethylene glycol)
US6992168B2 (en)Sterically hindered poly(ethylene glycol) alkanoic acids and derivatives thereof
HK1132001A (en)Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)

Legal Events

DateCodeTitleDescription
ASAssignment

Owner name:NEKTAR THERAPEUTICS AL, CORPORATION, ALABAMA

Free format text:CHANGE OF NAME;ASSIGNOR:SHEARWATER CORPORATION;REEL/FRAME:013467/0564

Effective date:20021202

STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

ASAssignment

Owner name:NEKTAR THERAPEUTICS, CALIFORNIA

Free format text:MERGER;ASSIGNOR:NEKTAR THERAPEUTICS AL, CORPORATION;REEL/FRAME:023196/0394

Effective date:20090731

Owner name:NEKTAR THERAPEUTICS,CALIFORNIA

Free format text:MERGER;ASSIGNOR:NEKTAR THERAPEUTICS AL, CORPORATION;REEL/FRAME:023196/0394

Effective date:20090731


[8]ページ先頭

©2009-2025 Movatter.jp